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ABSTRACT
The Regulators of Complement Activation gene cluster on
chromosome 1 includes genes fOI: I:egulatol:y proteins wl1ich
interact with complement component C3. ThE! general aim of this
project was to explore genetic 'lariation and/or immunological
function of certain of these proteins.
One specific aim was to assess fa..:tor 11., fact"r 1 and
complement receptor 2 (CR2) genetic polymorph isms. An
immunodetection system ....as c'evclopcd to iGcnt i [y r"ctor U
varLants separated by isoelectric focusing. The method is
economical and suitable for population surveys. AUcle
frequencies estimated from 129 serum samples arc FU.l 0.59'1
and FH*2 0.403. No association was observed bet.....een factor II
types and rheumatoid arthritis. A new variant, IF*IJ1, ....iI~
found ""hen 288 Caucasians were typed for Factor I. 'fhe resul ts
from this survey also indicated that IF*A is present at a much
lower frequency in caucasians than in Asi~.tics. SDS-PAGF:
followed by immunoblotting was used to dc[ inc a new, 75 kl)a
variant (CR2 L) of CR2 (CR2 H). six CR2 L hctct"o~ygotcs and
one homozygote were observed in 63 unrelated samples and
segregation of CR2 L was demonstrated by a family study. now
cytometry analysis of the binding of EDV and various anti-CR2
monoclonal antibodies to a CR2 L homozygous cell line did not
ii
clarify the 1II01ecular basis for the reduced size of CR2 L.
A second specific objective was to explore.in.....Yl.Y..2. usinq
a mouse model. the regulatory role of CR2 in the i1llmune
response. Pretreat.ent with anti-CR2 siqnificantly depressed
the primary response (mainly IgM) to aT-dependent antiqen and
impaired the generation of immunologIcal memoxy, but did not
oradicate an already established immunological memory. The
suppressive effect was different from that initiated by cobra
venom factor pretreatment (C3 depletion) where only the
primary IgG response was affected. Antigen complexed with
anti-CR2 is physiologically analogous to C3d-Ag-Ab. Ag-anti-
Clt2 complexes evoked an~ secondary response at a 100-
(old lower 1\q dose than 1\g alone. Taken together, these
results suggest, but do not prove, that (i) when stimulated by
a single signal from CR2, B cells can become anergic and (ii)
CR2 can enhance the secondary response either by signalling
via CR2 cornplexed to IgM or CD19. or by localizinq Aq-Ab
complexes on follicular dendritic cells.
KEY WORDS: Factor II Factor I CR2 Polymorphism
Immune response
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CHAPTER 1
INTROOUCTION
1. His-i:ory of complement research
Study of the complement system began in the late 19th
century when scientific debate was focused on the mechanisms
by which the body defends itself against microorganisms. At
that time there ",ere two distinct schools of thought:
"cellular immunity" versus "humoral immunity". A group of
humoralist giants, lncluding Buchner, Ehrlich and Dordct,
demonstrated that bacteriolysis required two factors in the
bloodstream, a heat-stable factor (antibody) and a hcat-lilbile
factor (called alexin and later designated "complemont"). Over
the next two decades, accumulated evidence provided by the
pioneering work of Ferrata, coca, Whitehoild and others
indicated that complement was a complex rather thiln a single
'Substance. This complexity of the complement system wall not
clearly elucidated until the 19405 when the development of
protein purification and electrophoresis allowed indivjdual
complement components to be charilcterized. The nomenclature of
complement components was simplified by the WHO committee in
1968. with the help of recombinant DNA technology, a numbel" of
studies from the past two decades have enriched and broadened
our understanding of complement proteins with special emphasis
on the correlation of structure and function. The discovery of
cell-bound complement receptors shed new light on the
biological importance of the complement system. Here, the
biochemistry of complement components, activation pathways and
biological functions are summarized from various reviews
(Muller-Eberhard, 1988: Campbell et al.., 1988; Mollnes and
[..lchmann, 1988; Hourcade et al., 1989; Kinoshita, 1991; Sim
and Reid, 1991; Colten and Rosen, 1992).
2. The complement cascade
Complement is a major defence and clearance system that
ferms the principal effector arm of humoral immunity. Today,
it is known that this system is a group of more than 30
different proteins, present in serum and on cell surfaces,
shown in Table 1.1. Most solUble components are synthesized by
the liver, although some are extrahepatically produced at
local sites of injury and inflammation. Hepatocytes,
mocrophages, fibroblasts and epithelial cells are major sites
of synthesis and secretion. Tile membrane-bound regulatory
components, of course, are synthesized in the cells on which
they are expressed. Activation of the complement system
Table 1.1. A summary of biochclJIi'::i\l ,md st,"uctm""l f~'.ll"III""~' llf
complement components, rC<Julatocy protein'1, ,Ilul IIl·mllr".IIlt'
receptors.
Number Conccn- stnlctlll",t!
Componcmts m.w. of tr.,tioll re.ltlll"o~~;
(kDa) chains (uq/lJI1)
Classical
pathway
e,
e'q 460 '0 00 Col t ..rwn-I il;,'
e'r '66 5(1 :;(~ .. ; nl'
Ill'oh',l~;", : ; ( 'l~
e1, '66 50 :~cr"irw
prot<.~;H'", :;1:11
C< 205 "OO-~~,O 'I'h i Ol~~\ll'r
cUlll"..linil\'J
e2 102 :10 ::lll'i",·
l>I"ot".I~;o,, ::\'1(
185 l,:IOU ::im;ld'" tn e'l
11.1tornativo
pathway
Factor 0
"
:;r.r i 'u~ l' ... II "" ~:"
Factor B 92 210 :;.~r i 11'" l'l""t.!ill,
:;cu
e3 lB5 1, )OU :;;111;1,11 tn 1:4
TOrJIinal
proteins
e5 '90 '/0 :;irnil.lI" tn
C"ljr:<l
CO 120 6' I'orr·-r"nni II,!
lH·"tnin, ::t:ll
e., 110 50 :;ilililitr L" f:',
CO 155 !.fJ l'nn,-I'lnlli"'J
jll"ill:,·ill
e9 7J !;") l'tJl"'~-lqn"ill'l
__"l~~t.:~~~1
'l'iJlllc 1..1. (continued)
"umber Conccn- Structurtll
Cornpunentn of tration features
(kOa) chains (ug/ml)
nOfJulatory
protoins
r!i!.~.p.llD.
Cl- illl! ihitor. UO 200 Serine protetlse
inhibitor
eil-bind jng 570 250 SeR
pr.otcin
Propcrd in 220 3 or 4 20 CyClic polymer
FilctOr. II 150 480 SCR
f'i1cto[" I no 35 Serine protease
S-protcj n B5 505
H!.llJ\I:!r:{!n~
11M' (CD:>5) ./0 N/A SCR
rJlCI' (CIl·H') 45-70 N/' SCR
IIHF 01: (CUllp) (,5 N/' Phosphatidyl-
inositol anchor
"Hill, (CIW)) 20 N/' Phosphatidyl-jnositol anchor
Complement
receptors
CI~l (Cll)~) 160-250 N/' SCR
CH2 (CO2!) 14S N/' ScR
CIO 1.65 'oj N/' Leukocyte(Clll1bjClllB) 95 (~I integrin
ell'l 150 (0) N/' Leukocyte(CllllcjCIHO) 95 (P) .i.nt~grin
Clq receptor
"
N/'
CJ,,/C,lu N/A
rcccptol-
C~u t"cL:cptor 50 N/A G protein
coupling
NjA, not app.l ~cable
initiat~s a sequence of biochemical reactions, each component
activating the next in a cascade faahion. There are two
distinct routes to activate the system: the classical and
alternative pathways. Both pathways lead to the generation of
C5 convertases that induce terminal assembly of the membrane
att::;,ck complex (MAC) C5b-C9, as shown in Figure 1. 1.
2.1. Complement activation
The classical activation pathway
The classical pathway can be initiated primarily by
interaction of CI with antigen-antibody complexes or
iJTllllunoglobulin aggregates (IgG or I9M). Cl is a multimeric
complex containing Clq, Clr and CIs subunits. Clq is a
multichain moleculE< with a collagen-like stem po['tion and six
globular heads. Multivalent binding of Clq, via its heads to
specific sites in the Fc region of IgG or. IgM, leads to
conformational changes within Clq and CIl" and l"esults in the
activation of Clr and CIs. Subsequently, activated CIs, a
serine esterase, splits C4 into two fragments, C4a and C4b. By
the exposed internal thioest€'- group in the cz chain, C4b can
covalently bind to OH- or NHz-groups on the target surfaces.
The next stage involves the binding of C2 to C4b in the
Classical Pathway
Alternative Pathway
Ag.Ab lomPlex
C1
J
C2
I
C4 ---> C4b --->C4b2a C4b2a3b
.......,.
C3 C3b CS
C3 ~ C3b ---> C3bBb (C3b)n~
I I
C3(H,o) Bb B
o r_ Microbes
Polysaccharides, etc,
C3(HP) B
C7 C9
\. 1\ Membrane
,> ,> ) Attack
I I Complex
1 1
C5 CB
Figurc 1.1. Complcmcnt System Acti"ation
presence of magnesium ions. Following cleavage by activated
CIs, C2a, a large fragment, remains asscciated with C4b to
form a C4b2a complex, which is the classical-pathwiJY C3
convertase. C2a in the complex cleaves C3, releasing <In N-
tenninal fragment C3a. The remaining portion of C3, the C3b
fragment, undergoes a conformational change and binds to the
target surfaces in the vicinity of the C4b2a complex via an
ester or amide bond. Thus, the target-bound C4b2a3b complex,
the classical pathway C5 convertase, is formed.
The alternative activation pathway
The initial interaction which triggers the alternative
pathway is not understood as well as that for the classic.. l
pathway. The alternative pathway activation docs not depend
upon antibody-antigen complexes; rather, a wide range of non-
immunoglobulin activators such fungi, yeast,
lipopolysaccharides, can mediate activation. It rei ies on the
continuous activation of CJ by a low-level hydrolysis in the
fluid phase. This results in the formation of CJ(Hpl capable
of binding factor S, and in the presence of factor D, in the
formation of the alternative pathway CJ convQrtase (C3bBb),
which functions the same way as the C4b2a of the classical
pathway to produce more CJb fragment. Next, CJb is deposited
on the target surfaces, and eventually becOllles the C5
convertase (CJbBbC3b) of the alternative pathway. Compared to
the classical pathway, CJ convertase (CJbBb) initiates the
activation of IIore and lIIore C3 by a positive feedback cy.::le.
Thus, the alternative pathway ot complement activation
provides a quick, nonspecific natural defence system.
Activation of C5 and Assembly of the membrane attack comph!x
(MAC)
C5 can be activated by either the classical (C4b2aJb)
the alternative (CJbBbCJb) pathway. Atter cleavage of C5 by
the C2a or Bb subunit of the C5 convertases, the smaller
fragment, C5a, is released into the fluid phase and the larger
one, C5b, remains attached to the target surface:> and
expresses transient binding si tes for C6. The CSb-6 complex is
subsequently stabilized by binding of C7. C8 and C9. It has
been widely accepted that C9 in the MAC is present in multiple
copies frolll 12 to 18. Although the complex C5b-8 is lytic,
incorporatior. of C9 to the complex greatly enhances membran9
perturbation and increases the size of the transmembrane pore,
giving a higher efficiency of lysis.
2.2. Control of complement activation
Like any cascade system with a rapid and amplified
reaction, the complf'ment cascade must be strictly controlled,
otherwise a vast amount of a ... tive intermediates from
continuous activation can cause cell damage and even death. At
several stages the control of complement activation is ensured
by two different mechanisms: natural decay processes and
active regulation. Natural decay processes occur in two ways:
First, in the absence of a substrate, an active binding site
will usually be inactivated over a period of milliseconds.
Second, the proteins constituting a converta~e '01111
spontaneously dissociate from each other, a process that
usually takes minutes. Active regulation, performed by
inhibitor/regulatory proteins, also occurs in different ways.
Spontaneous dissociation of a convertase can be facili tated by
a regUlatory protein. Alternatively. the individual proteins
can be inactivated, either by changing the structure of the
protein, or by degrading it into t ....o or more pieces.
Cl level:
Control at the stage of Cl activation is achieved by Cl
inhibitor, a plasma serine esterase. It not only restricts the
half-life of activated Cl but ..Iso dissociates Clr and CIS
from Clq. Inhibition of activated CI involves the covalent
bindin9 of Cl-INII to the catalytic sites on CIr and CIs,
followed by dissociation of these molecules froJ'll Clq. Cl
inhibitor is also a potent inhibitor of other serine esterases
such as plasma kallikrein, factor XIa, factor XIIa and
plasmin. People with genetic deficiency of Cl inhibitor suffer
from hereditary angioedema.
C3-convertases:
Several proteins are involved in control at the stage of
assembly and decay of the C3-convertases (C4b2a in the
classical pathway and C3bBb in the alternative pathway).
Characterization of these regulatory proteins is shown 1n
Table 1. 2.
Dissociation of C2a from C4b is accelerated by C4b-binding
protein (C4BP) which competes with C2a for the binding sites
on C4b. C4BP then acts as a cofactor to render C4b susceptible
to cleavage by the serine protease factor I. Similarly, the
dissociation of Bb from C3b is accelerated by factor H, which
also acts as a cofactor for cleavage of C3b by factor I.
Properdin, present in the form of a mixture of cyclic polymers
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Table 1.2. Proteins involved in the control and ,"clJlIl.ltinll of
CJ convcrtascs
Enzyme Decay Cof... ct.or ~la i n
Proteins Ligands activity accclcl";\- 'u.:l:ivit:y ronll!"CC:;
tion
Factor I C3b/C4b
Factor II CJb
C4BP C'b
Properdin C3bBb
CRl C3b/C<lb
iCJb
CR2 CJd
CJdg
OAF CoIb2a
CJbBb
HCP CJb
l'l;tmn;l
PI ,'):lm;1
1'1;1:11\1;\
stflbi l i O':cu
C3/C5
convcr-
tascs
1-:, I'MfI II,
:lomu 'I',
"'DC,
l'l"tulet
M"Il":;
II, I'IK;
;1 lew 'I'
Abbreviations: E I erythrocyte::>; PHil, pu 1ymorphollllil I ell I'
leukocytes; B, n lymphocytes; 'r, 'I' Jylllphor;yl:l::;; FllC,
follicular dendritic cells; Monos, monocytc:.:; I'JlI,. pt~I-iflllOr;IJ
blood leukocytes.
II
of a 56 kDa polypeptide, is another regulator in the
alternative pathway. It has the opposite effect of factor H,
~ it stabilizes the alternative C3 convertases, thus
preventing the inactivation of C3bBb by factor I and H. Factor
I is a regulator enzyme involved in the cleavage of the a'-
chains of activation products (CJb and C4b) of complement C3
and C4. These specific cleavage reactions cause C3b and C4b to
lose their ability to function in the C3 convertases.
Regulation of C3 convertases is also mediated by membrane-
bound m;:)lecule5l, including decay accelerating factor (OAF,
CDSS) , membrane cofactor protein (HCP, CD46), complement
receptor type I (CRI, CD35) and probably complement receptor
type 2 (CR2, C02I). The genes encoding these six complement
proteins, CRl, CR2, OAF, KCP, C4BP and factor H are closely
linked on chromosome I in a region now known as the regUlators
of complement activation gene cluster (RCA). The RCA protein
group is also sometimes called the superfamily ;)f CJbjC4b
binding proteins, based on their ligand binding abilities,
functional similarities and genetic linkage. The structural
and functional characterization of factor I and its six
co factors will be reviewed in detail in CHAPTER 2.
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C5 and the membrane attack complex (HAC):
Control of the C5b-7 complex is mediated by several plasma
inhibitors. The S-protein is the most efficient and probably
the major controlling factor of the lytic potential of the
MAC. This glycoprotein with a single chain of 80 kOa can bind
to CSb-7, forming a SC5b-7 complex. The binding of s-protein
thus prevents the CSb-7 complex from binding to the cell and
therefore protects bystander cells against lysis by the HAC.
On the membrane, the homologous restriction factor (HRF) known
as C8 binding protein (C8bp), and the membrane inhibitor of
reactive lysis (MIRL, CD59), have the capacity to regUlate the
assembly of the MAC, by inhibiting the binding and
polymerization of C9. It is kno....n that human complement Is
more efficient at lysing erythrocytes of other species than at
lysing homologous erythrocytes. This phenomenon has been
termed homologous species restriction of complemC!nt-mcdiated
hemolysis. This may also be the case in other species. IIRF' is
a 65 kDa protein and is localized on erythrocyte and leUkocyte
membranes. Whereas DAF', MCP, CRI and probably CR2 rC!gulate
activation on the membrane at the level of CJ convcrtases, HRF
serves to control the final assembly of the terminal
complement complex to protllct autologous cells against
complement-mediated lysis. It is able to inhibit the channel-
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forming function of both polyC9 and C5b-8. There is an
abnonaally high amount of hemolysis in patients .... i th
paroxysJlIal nocturnal helloglobinuria (PHH), a disease in which
cell lacks HRF. The complete functional role of HRP is yet to
be defined.
Membrane Inhibitor of Reactive Lysis (MIRL) is an 18 JeDa
glycosyl phosphatidyllnositol-anchored membrane protein that
inhibits complement-mediated lysis by binding to C5b-8 and
inhibiting C9 multiplicity. It also appears to modulate the
activity of the alternative pathway C3 convertases, although
the mechanism of regUlation has not been elucidated.
3. The Biological Role of complement activation
The complelllont system is one of the .ost important humoral
systems mediating .any activities that contribute to
inflammation and host defence, even in the pre immune phase
when specific antibody and lymphocytes are not available.
Activation of the complement system results in the production
of molecules with potent biological activities. The major
biological functions of these activation fragments are exerted
by binding to their specific receptors.
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Inflammation: Activation of the complement system by an
infectious agent causes the release of three anaphylatoxins,
C3a, C4a and C5a, from their parent molecules. They are very
similar in structure and mediate a similar set of activities
but with different efficiencies (C5a » CJa » C4a). The
anaphylatoxins induce smooth muscle contraction and enhance
vascular permeability by binding to specific receptors and
inducing the release of vasoactive amines such as histamine
fron: mast cells and basophils and lysosomal enzyme release
from granulocytes. C5a functions also as a chcrnotaxin,
inducing the migration of leukocytes into an area of infection
or tissue destruction.
Cell lysis: Complement was originally discovered by its
lytic activity. Insertion of MAC into the cell membrane
results in membrane disturbance and leakage of intracellular
material. Complement-mediated lysis has been shown for many
kinds of cells: platelets, Gram-negative bacteria, viruses
possessing a lipoprotein en':elope, and lymphocytes.
opsonization and phagocytosis: Phag....cytcs are ,)ble to
ingest and eliminate cell debris, immune complexes and foreign
microorganisms only if they can recognize and distinguish them
from host cells. This requires that these targets have been
IS
marked by antibody and/or complement fragments. This process
of coating targets with antibody and/or complement fragments
is termed "opsonb:ation". The phagocyte population includes
macrophages, manocytes and polymorphonuclear leUkocytes.
Phagocytes use their Fc receptors for arrent of antibody-
coated targets, and use their complement receptors for capture
of targets coated by C3 fragments. The interaction of Fc
receptor and antibody is sufficient to trigger the ingestion
process provided the level of antibody on the target is high
enough to initiate a stable binding to phagocytic cells. In
the case of only a small amount of antibody on the target,
active C3b and C4b fragments deposited on the target will
facilitate uptake by phagocytes by enhancing the efficiency of
phagocyte binding via the complement receptors.
Immune complex clearance: Interaction of antibody and
nntigen in...::!J..Y.2. can result in the formation and precipitation
of a large immune complex. ~, precipitation of immune
complexes in tissues is strongly inhibited by complement. The
size of the complex famed is dependent on the ratio of
antigen to antibody and, once it reaches a certain size,
maximum precipitation occurs. Preformed immune complexes can
be solubilized by the action of the alternative pathway
components C3, Band D, resulting in both antigen and antibody
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in the complex becoming coated \o/ith CJb. Association of IgG or
IgM antibodies with antigen initiates the classical pathway
component Cl activation. Binding of Cl to the immune complex
also causes inhibition of precipitiC'tion, followed by CJb
coating of the complex. Once immune complexes are coated with
CJb, they can be recognized by the CRl receptor on red blood
cells and eliminat'ed from the circulation by monocytes in the
bloodstream or by macrophages in liver and spleen.
ImmUDB regulation: Although the complement system has been
studied for over a century, possible roles in the immune
response for the various complement components and fragments
were not fOX"lllulated until the 1970's. :'his topic will be
addressed in detail in CHAPTER J.
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CHAPTER. 2
FACTOR I. ITS COFACTORS AND RELATED PROTEINS
2.1. Factor I
2.1.1. Biochelllical properties
Factor I (formerly CJb inactivator, CJbINA) is involved in
the regulation of the CJ convertases of either pathway. Human
factor I is synthesized in liver and in extrahepatic tissues
(monocytes and endothelial cells) as a single chain precursor
of 88 kDa. which is then processed to yield the active form,
of two disulfide-linked chains of 50 kDa and 38 kDa. Factor I
1s found in plaslla at a concentration of about 3S ug/1Il1
(Pangburn et a1.. 1977). It has been suspected for SOMe time
that factor I .ight belong to the serine protease fallily.
Definitive evidence was obtained from amino acid sequence
studies on the 38 kDa light chain which showed the presence ot
the characteristic set of residues found in the active sites
of other serine proteases such as chymotrypsin and trypsin
(Yuan et a1., 1986).
\8
2.1.2. Genetics
The known amino acid sequence of the 38 kDa light chain of
factor I was used to generate oligonucleotide probes which
allowed the isolation, from a liver cDNA library I of a clone
containing the whole of the coding region (catterall et aI.,
1987). The mRNA size in liver is 2.4 kb and the cloned DNA has
1750 bp encoding the single polypeptide chain of 565 amino
acids. The sequence includes a putative leader peptide of 18
residues, a cysteine rich (29 Cys residues) heavy chain of 317
residues and a catalytic light chain of 240 residues. six
potential N-linked glycosylation sites are also seen.
Activation of the precursor factor I probably involves the
limited proteolysis and trimming of a highly basic peptide
sequence (-Arg-Arg-Lys-Arg-) located at the C tet"lllinus of the
heavy chain. The gene for factor I has been mapped to human
chromosome 4, at q25, by the somatic cell hybr id method
(Goldberger et al., 1987; shiang et al., 1989).
A number of cases of complete deficiency of factor I have
been reported (Rasmussen et aI., 1988). The RFLPs of factor I
have been identified in a stUdy of several factor I-deficient
klndreds (Kaible et al., 1989), but little is currently known
about the mutant genes. Inherited deficiency of factor I is
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usually associated with increased susceptibility to infection
by pyogens such as pneumococci, Hemophilus influenza, and
meningococci. Some patients exhibit circulating immune
complexes and/or recurrent urticaria. As wouh! be expected
from the regulatory role of factor I, affected individuals
have little or no native C3 in their plasma due to the
uncontrolled formation of the C3bBb complex which splits C3.
Infusion of factor I in.....Y..iY.2 restores the serum concentrations
of the complement proteins (C3, factor B, etc.) to normal
values in the patients (Rasmussen et al., 1988).
Genetic polymorphism of factor I was first found by
NakamUl"a et a1. (1985) in the Japanese population. using
polyacrylamide gel isoelectric focusing electrophoresis of
neuraminidase-treated EDTA plasma samples follo....ed by western
blotting, 435 unrelated individuals and some families living
in the Tokyo area were typed. Tnree different phenotypes
controlled by two alleles, ....ith frequencies of IF*A (acidic)
0.1069 and IF*B (basic) 0.8931, of a single locus were found.
One year later, Nishimukai et a1. (1986) published the second
report of Factor I polymorphism in the Japanese population and
described a modified method of typing. The gene frequencies of
the two alleles calculated from this study in the western part
of Japan were similar to those pUblished by Nakamura et a1.
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The two allelic variants of factor I differ by charge and size
homogeneity has been verified by sodium dodecyl sulfate (50S)
polyacrylamide gel electrophoresis. There has been no DNA
sequence information from individuals with different
phenotypes to account for the charge polymorphism. Nor are
there any functional differences between the two forms. Factor
I polymorphism provides a new marker for human genetics,
anthropologic studies, and for.ensie science. Further
investigations may provide useful information ,lbout the
deficiency of factor I.
2.1.3. Immunological function
The third component of complement, CJ, l:onsists of two
polypeptide chains (a 110 kOa Q-chain and 75 kOa ,a-chain)
linked by one disulfide bond and by noncovalent forces
(Bokisch et aI., 1975; Janatova, 1980), as shown in Fig. 2.1-
It contains two N-linked carbohydrate moieties at resldueG 63
and 917, with 8-9 and 5-6 mannose residues, respectively.
During complement activation CJb is produced by proteoJytic
cleavage or the CJ a-chain by the classical (C4b2a~ or
alternative (C3bBb) pathway convertascs with release of the
amino terminal C3a peptide (Reid and Porter, 19R1). The
nascent C3b has a labile binding site and binds covalently t.o
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C3 degradation
target molecules through an ester or amide bond to nearby
hydroxyl or amino groups (Reid and Porter, 1981; Law et al.,
1983). Factor I, which controls the concentration of C3b bound
or in the fluid phase, is an essential part of the regulation
of complement activation. The digestion of C3b by factor 1
proceeds in several steps and requires the presence of one of
several cofactors (Reid et al., 1986; Mitomo at al., 1987).
The first two cleavages of the a-chain of C3b by (actor I
occur between Arg-Ser residues a.t positions 1281-1282 and
1298-1299, liberating a 2-kDa C3f-fragment and yielding iC3b.
This degradation of C3b to iC3b is accompanied by
conformational changes of the molecule. An additiona 1 factor
I cleavage site exists between residues 932-933 (Arg-Glu) in
iCJb generating CJc and C3dg (Ross et al., 1982; Lachmann et
al., 1982; Davis et at., 1984). Further proteolysis of C3clg by
trypsin, elastase or plasmin generates CJd. These CJ
fragments, both soluble and/or surface bound, generated during
complement activation can bind specifically to several cell
surface recaptors (Bacherer et al .• 1989).
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2.2. Factor H
2.2.1. Biochemical features
Factor H is a single chain glycoprotein of 150 kDa which
acts as the main soluble regulatory protein involved in the
acceleration of the decay of C3bBb and as a cofactor in the
factor I-mediated breakdown of C3b to iC3b. It is likely that
factor H also rogulates the C5 convertasc since it competes
with C5 for CJb (Isenman et al., HSO;, Disciplo, 1981).
Factor H hus been described in a ..umber of species including
man. It has been found to be very similar both chemically and
functionally in all species where it has been described. The
concentration in plasma is 500 ugjml in man, 230 ugjml in mice
and 130 ugjml in rabbit (Kristensen et al., 1987). In addition
to its presence in serum, factor H is also foun~ on the cell
surface of monocytes and lymphocytes, although its role here
is unclear (Sim et al., 1986). A factor H membrane receptor
has been identified on B cells and monocytes (Lambrls and
Ross., 1982).
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2.2.2. Genetics
Factor H polymorphism has been described in humans and mice
(Rodriguez de Cordoba and Rubinstein, 1964; Natsuume-Sakai et
aL, 1964). There are five allelic variants which differ by
charge. This can be demonstrated using high-resolution
isoelectric focusing of immunoprecipitated proteins under
denaturing conditions. Each of the variants of factor H
consists of one major band and four minor bands, two with
slightly higher pI values and two slightly lower. The nmge of
pI for all of the bands is 6.50-6.75. Basad on the analysis of
206 unrelated Caucasians living in New York city, the gene
frequencies for the factor H alleles FH*l, FH*2, FH*3, FI/*4
and FHlIS are 0.665, 0.301, 0.006, 0.002 and 0.006,
respectively.
Factor H variations at the eDNA level and in amino acid
sequence have also been observed. The complete eDNA coding
sequence has been derived from overlapping clones, and a
polymorphism at base 1277 has been characterized (Day et aI.,
1988). In four clones there is a T at nucleotide 1277 and in
two others there is a c. This TiC change represents a
Tyrosine/Histidine polymorphism at position 384 in the derived
amino acid sequence. Protein sequence studies on purified
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factor H froID pooled plasma from 12 donors confirmed the
presence of both tyrosine and histidine at this position.
Tyrosine and histidine ....ere observed in a ratio of 2 : 1,
respectively. This polymorphism is likely to represent a
sequence difference bet....een the t ....o most abundant charge
variants, FH 1 and FH 2. A Bql II RFLP of factor H has also
been observed.
eDNA clones have been i~olated and sequenced in both humans
and mice. The derived amino acid ~(;l.quence indicates that the
mature protein consists of 1213 residues in humans and 1216
residues in mice (Kristensen et al., 1986; Kristensen and
Tack, 1986), and the two sequences are 61% homologous. Both
human and mouse factor H are composed of 20 consensus
repeating units of 60 amino acids. For human factor H, three
different mRNA spncies are abundantly expressed in liver: 4.3
kb, 1.8 kb and 1. 4 kb. The 4. 3 kb mRNA codes for the common
factor H of 150 kDa (Sch....aeble et al., 1987). The sequence
analysis of the 1.8 kb mRNA showed that this species is
largely identical to the 5' portion of the 4.3 kb mRNA,
suggesting that the 1.8 kb and the 4.3 kb mRNA arise by
alternative splicing from a single structural gene (Estaller
et al., 1991). The 1.4 kb lliRNA is highly homologous to the 3'
end of the 4. J kb mRNA of factor H (Schwaeble et al., 1991).
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The translation of the 1.8 kb mRNA is believed to produce two
truncated forms of factor H, 43 kDa and 37 kDa, respectively.
which have been identified in human serum by immunoblots using
antisera against factor H (Estaller et al., 1991). The smaller
product may be a cleaved form of the larger one. Both proteins
are distinct in site from the common proteolytic products of
factor H. The function and activity of these truncated forms
of factor H are unclear, although they contain a sequonce
corresponding to the C3b-binding site. The t-'rcduct of the 1.4
kb mRNA is still unknown.
The chromosomal location of factor II has been determined in
both hUmans (Hing et al., 1988) and mice (D'Eustachio et al..
1987). The human factor H gene is within the cluster of genes
of RCA on the long arm of chromosome 1 (Rodriguez de Cordoba
et al., 1985). Linkage analysis has suggested that the human
factor H gene is approximately 6.9 eH from the rest of the
genes of RCA (Rodriguez de Cordoba and RUbinstein, 1987), and
gene mapping by pUlse-field gel electrophoresis has confirmC!d
this finding (Rey-Campos et a1.. 198B).
A number of patients have been reported who a re homozygous
or heterozygous deficient in factor H, and the defect at tho
DNA. level has been identified (Brai et aI., 198B;). Clinical
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Ilanifestations are quite variable. SOlie patients appear
sYlDpto. free while others have recurrent pyogenic infections
(Neisserial llIeninqitis) lIlembranoproli ferative
glomerulonephritis (Nielsen et al., 19891 Day, 1986). The
reason for these differences in clinical expression between
the two deficiencies (ho.ozygous vs heterozygous) is unclear,
since both deficiencies result in increased complement
activation and cleavage of CJ.
2.2. J. Immunological functions
Factor H is the most abundant cofactor protein in the
control of the alternative pathway or complement activation.
First, it can compete with factor B for C3b binding (DiScipio
et al., 19B1). Second, factor H can disasse~~e C3 convertasB
by facilitating dissociation of Bb from C3b (Whaley and Ruddy,
1976). Third, factor H can inhibit C5 convertase by cOllpetinq
\lith C5 for C3b binding (DiScipio et aI., 1981). Fourth,
factor H can act as a cofactor for factor I to specifically
cleave C3b, t1:'~reby inactivating it (Whaley and Ruddy, 1976:
Pangburn et 211.. 1977).
Several reports have identified different regions of CJb
that are involved in factor H binding, suggesting that factor
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Hand C3b interact" via multiple sites. One of the factor H
binding sites has been localized within the C3d fragment by
using anti-factor H (human) anti-idiotypic antibodies and
synthetic peptides. The binding site appears to be
discontinuous spanning residues 1187-1249 of CJ (Lambris et
al., 1988). Another site in C3b which mediates factor H
binding has been localized to the n-terminal 40 amino acids of
the a' chain, based on the inhibition of factor H binding to
C3b by anti-C3c or anti-C3d polyclonal antibodies and by
synthetic peptides. This domain of C3b (residues 727-768 of
the N-terminus of the a' chain) has also been identified as a
site of interaction for CRl and factor B (Becherer and
Lambris. 1988: Ganu and Muller-Eberhard, 1985).
The binding site on factor H for C3b has been localized by
the use of monoclonal anti-factor Il antibodies and proteolytic
cltOlavage fragments of factor H (Alsenz et a1.. 1985). The
trypsin-cleaved 38 kDa fragment at the N-terminus of factor H
showed both the C3b-bindinq activity and the cofactor
activity. Physical and electron microscopic studies indicated
that factor H has an elongated shape ....hich, as for C4BP, may
be a consequence of the presence of 20 homoloqous short
repeats of 60 amino acids.
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C4b-bindinq Protein (C4BPI
2.] .1. BiocheJlical features
C4BP is a carbohydrate-rich plasma protein functioning as
a regulator of the classical pathway of the complement system.
It is the largest of the complement proteins beinq
approxiJlately 570,000 daltons. The concentration of C4BP in
plasma is about 280 ug/ml in hUlIans (Scharfstein et aI., 1978,
Fujita et aI., 1978). C4BP is synthesized in the liver and its
synthesis and secretion by hepatoma cells is enhanced by
interleukin-6 and tumor necrosis factor, suggesting that C4BP
is an acute phase protein (Hessing, 1.991). Human C4BP is
COJ'lposed of eiqht Chains, seven identical 71 kDa polypeptides
(0 chain) and one 4S kDa po1.ypcptide IP chain). Each a chain
contains 549 a.ino acid residues (Chung et a1., 1985; Lintin
and Reid, 1986). The N-termi.lal 491 residues can be divided
into eight repeatinq, but not identical. homology regions of
60 amino acids ot the RCA type, as described earlier (p 251.
The 13 chain consists of 235 allino acids and the calculated
molecular mass is found to be 26.4 kDa. which is in contrast
....ith the estimated mass of 45 kDa derived from gel
electrophoresis (Hil1arp and Dahlbaclt, 1990). The difference
is caused by qlycosylation of the mature molecule. The {J chain
JO
has three seRs. The two cysteines in the C-ternina1 regions of
both Q- and ,8-chains are thought to be involved in the
interchain disulfide bridges. Electron microscopic studies of
C4BP have suggested that C4BP has a spider-like structure with
seven elongated tentacles (a chain) extending from a central,
ring-like core (11 chain) (Oahlback et al., 1983: Dahlback and
Miiller-Eberhard, 1984). X-ray and neutron scattering studies
suggest that C4BP in solution resembles a more rigid bundle of
seven arms in contrast to the splayed-out images seen in
electron micrographs (Perkins et al., 1986). The binding sites
for C4b are located at the peripheral half of each a-chain
(Dahlback et aL, 1983; Fujita et a1., 1985) and it has been
reported that up to 4 molecules of c4b can bind to one C4BP
molecule (Scharfstein et al., 1978).
C4BP appears in two forms in plasma, as free protein and in
a noncovalent complex with the vitamin K-dependent coagUlation
protein, protein S (Dahlback, 1983). When C4BP binds to
protein S, it inhibits its anticoagulant activity. C4BP
contains one single binding site for protein S on the central
core, which is distinct from the multiple binding s1 tes for
C4b (Hillarp and Dahlback, 1987; Suzuki and Nishioka, 1986).
So far, no clear physiological function for the ,ASP-protein
S complex has been found.
31
2.).2. Genetics
The huun C4BP gene spans about 28 kb and has been mllpped
to chro.aosome 1, band 1q32, with other qenes of the RCA group
(Lintin and Reid, 1986; Hing et aI., 1988; Rey-caDpos et al.,
1988; Carroll et al., 1988). The qenes tor both the a and the
f3 chains are closely linked in a head-to-tail arrangement
(Pardo-Manuel et al., 1990). Since the mRNA for C4BP is 2.5 kb
long, a large portion or the gene must be composed of intron
sequences. Human C4BP is polymorphic. In a sample or 516
unrelated Caucasian individuals, three genetic variants of
C4BP have been characterized by isoelectric focusing. The gene
frequencies of the three alleles are C4BP-l 0.986, C4BP-2
0.010 and C4BP-J 0.00', respectively (Rodriguez de Cordoba and
Rl'binstein, 1987). "BgI II RFLP has been detected within the
hUlian C.BP gene but since it was present in 50\ of the
individuals tested it is unlikely to shov any correlation with
the two common variants of protein polymorphism (Lintin and
Reid, 1986). No other RFLPs have been detected using other
restriction enzymes. However, a number at differences bet....een
the derived protein sequence frail the eDNA of an individual
and the protein sequence of C4BP isolated from pooled human
plasma have been found, suggesting that the protein tl'Iay have
more variants not yet detected by electrophoretic techniques
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and RFLP analysis at the protein and DNA levels, respectively
(Chung et al., 1985).
There is some documentation of changes in c.:.;p level 1n
diseases (Hessing. 1991). A moderate increase of C4BP levels
was observed in patients with acute pneumonia. Barnum and
Dahlback (1990) found that C4BP is e.'.evated in systemic lUpus
erythematosus. So far only one case ot" genetic def iciency of
human C4BP has been described in a patient with atypical
Behcet's disease (Trapp et al., 1987).
2.3.3. Immunological functions
C4BP regulates the activation of the classical pathway of
the complement system. It b able to bind to C4b displacing
C2a in the C3 convertase, C4b2a, and in addition it functions
as a cofactor for factor I in the proteolytic degradation of
C4b. The mechanism by ....hich the binding of C4b to C4BP turns
C4b into a substrate for factor I is unknown, but presumably
it involves a conformational change in C4b. Limited digestions
of human C4BP with chymotrypsin, trypsin and pepsin have
indicated that the cofactor activity for factor I is located
in the regi:'ln of residues 177-322 and that region 3)2-395 may
be important for binding to C4b (Chung et al .• 1985).
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~. 4. Decay Accelerating Factor (OAF, COSS)
2.4.1. Biochemical features
OAF is mainly found as a sin91e~chain inteqral membrane
glycoprotein of 70 kDa present on ,:he surface of a wide range
of cell types: erythrocytes, all leukocytes, platelets,
epithelial cells, and connective tissue (Kinoshita et a1.,
1985; Nicholson-Weller et a1., 1985). Leukocyte OAF has a
higher molecular mass than erythrocyte OAF, and biosynthetic
studies suggest that this is due to increased glycosylation
(Lublin et a1., 1986). There is a soluble form present at low
concentrations in extracellular fluids and tissue culture
supernatants (Medof et a1., 1987a).
Alternate forms of the membrane OAF molecule have also been
described. A larger variant, designated OA.F-2, was detected on
erythrocytes by Western blotting (Kinoshita et al., 1987).
OAF-Z possesses a molecular weight of 140,000, raising the
possibility that it is a dirner of DAF. OAF-2 represents less
than 10' of the total membrane OAF. The structure of DAF-Z
remains unexplained.
The primary structure was deduced from cloned OAF eDNA,
which encodes a polypeptide of 347 amino acid residues (Hedof
at al., 1987b; Caras at al., 1987). 8eginl11ng at the N-
terminus, the protein possesses four short consensus repeats
(SeRs) followed by a Ser and Thr-rich region and a hydrophobic
transmembrane anchor sequence of 23 c-terminal residues.
2.4.2. Genetics
The OAF gene was initially cloned from eDNA libraries from
Hela cells and HL-60 cells using oligonucleotide probes based
on the NH2 terminus OAF sequence. Linkage studies of RFLPs of
genomic DNA, somatic cell hybrids, and in situ hybridizati"n
localized the OAF gene to human chromosome 1, band q32; it is
part of the RCA gene cluster (LUblin et al., 1987; Rey-CampoD
et al., 1987). It is now known that the OAF gene is compolled
of 11 exons spread over 35 kb of genomic DNA and there arc two
species of mRNA products, one probably derived from the other
by a splicing event that induced a coding frame shift nC!ar the
c-terminus (Caras at al., 1987). The spliced mRNA, which
accounts for 90% of OAF mRNA, encodes membrane OAF, and the
unspliced mRNA produces secreted OAF. The OAt' gene is a single
copy (Stafford et aL, 1988) and genetic polymorphism of OAF
has been identified at the DNA level by RFLP analysis. Three
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RFLPs have been defined so far, two for the enzyme Hind III
and one for Bam HI (Stafford et a1., 1988; Post et a1., 1990).
serological polymorphism was also described by analysis of the
Cromer-related human blood group antigens (Cr'" o?"nd TC'") on the
OAF molecule (Telen et al., 1988).
:2.4. J. Immunological functions
OM" protects cells from autologous complement damage by
inhibiting the formation of CJ and CS convertases of the
classical or alternative pathways. It also accelerates the
spontaneous decay of the preformed CJ convertases. The preciso
mechanism underlying the interference with the CJ convertases,
and the specific binding sites for OAF on CJ.!" or C4b are still
uncle~.r. Furthermore, DAF has no cofactor activity for the
cleilvage of CJb or C4b by factor I (Pangburn et aI., 1983).
This is in contrast to the other membrane (CRl, CR:2 and MCP)
and fluid phase (factor Hand C4BP) regUlators of the C3
convertases which do act as cofactors for factor I.
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2.5. Membrane Cofactor Protein (MCP, CD46):
2.5.1. Biochemical features
Membrane cofactor protein was initially termed gp 45·, 70, to
reflect its electrophoretic mobility on SOS-PAGE (Cole et a1.,
1985). Except for erythrocytes, MCP has been found on nearly
every cell and tissue examined: peripheral blood leukocytes;
platelets; sperm; trophoblast; and cells of fibroblast,
epithelial, and endothelial lineages, including malignant cell
lines such as Kela (Cole et a1., 1985; Seya et al., 1986; 'iu
et a1., 1986; Seya et al., 1988; McNearney et al., 1989).
Peripheral blood leukocyte populations express 5,000-15,000
copies of KCP/cell to:hile hematopoietic lines express 30,000-
70,000 KCP/cell (Seya et a1., 1990; Cho et a!., 1991). 'rhc
protein has been purified, mUltiple eDNA cloned and sequenced.
It is composed of four short consensus repeats (SCRs) and is
a member of the RCA family. An unusual feature of MCP of human
peripheral blood mononucleilr cells and platelets is the
presence of two heterogeneous protein species of 59 - 68 kDa
and 50 - 58 kOa (Cole et aI., 1985). Prior to molecular
stUdies, MCP was characterized biochemically in order to
provide an explanation for the two species. It was found that
the shift in molecular weight could be accounted for in part
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by the variability in precursor forms, in carbohydrate unit
compositions and in glycosylation (Stern et aI., 1986; Ballard
etal.,1988).
2.5.2. Genetics
The MCP gene is situated on the long arlll of chromosome 1 at
q32 within the RCA cluster (Lublin et al., 1988~ Bora at al.,
1989). It consists of 14 exons and 13 introns and has a
minimum length of 43 kb (Post et al., 1991). At the protein
level, 72 unrelated individuals have been evaluated for MCP
phenotype on peripheral blood cells (Ballard et al., 1987).
Three stable patterns of expression were noted: predominance
of upper-forll pattern in 65\; equivalence of both forms in
29\; and predoJllinance of lower-form in 6\. Fa_ily studiQA
further supported a t ....o-allelic codominantly inherited system
regulating expression of MCP. It has also been determined that
the phenotypic pattern of KCP is the same on a given
individual's mononuclear cells (8 cells, T cells, and
monocytes) and platelets, and that the pattern is stable over
time (Ballard et aI., 1987; Yu et al., 1986). More recently,
a Hind III restriction fragment length polymorphism (RFLP) was
found that correlated with this pattern of expression (Bora et
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a1., 1991). This particular polymorphic site was traced to an
intron between exons 1 and 2.
No functional differences between the two major forms are
known, and no MCP deficiency has so far been described.
2.5.3. Immunological functions
The wide tissue distribution of MCP suggests that it plays
an important role. Like other RCA proteins, the CJb and C4b
binding sites on the MCP molecule would be expected to be
present within its four SCRs. By deleting one SCR and then
expressing the mutant protein in cos cells, Adams et al.
(1991) have demonstrated that MCP SCR-3 and SCR-4 are critical
for C3b binding While SCR-2, -3, and -4 are necessary for C4b
binding. These and other data suggest that the C3b and C4b
binding sites are distinct and that SCR-2 contributes more to
C4b than to C3b binding. On the other hand, it was also found
that a mutant lacking SCR-2 bound C3b but had no cofactor
activity. This suggests that ligand binding and cofactor
activity can be separated, and that there is a direct
interaction between a region within SCR-2 and factor I.
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Like CRI and factor H, soluble HCP acts as an efficient
factor I-dependent cofactor for generating iC3b fro. fluid-
phase C3b (Liszewski and Atkinson, 1992). However, this does
not lead to further degradation to C3c and C3dg. Also, unlike
CRl, HCP and factor H do not mediate the cleavage by factor I
cf iC3b to C3c and C3dg from membrane-bound C3b. No decay-
accelerating activity has been found for KCP.
2.6. Complement Receptor type I (CRI, C035)
2.6.1. Biochemical features
There are at least four receptors for C3 fragments, CRl,
CR2, CR3 and CR4 (Si1'll et a1. I 1987; Becherer et a1. I 1989). In
tables 1 and 2 the properties and biological effects of these
C3 receptors have been sUllUlarized.
Complement receptor type I (CRI) is a receptor for C3b and
C4b, the major fraglllents of activated C3 and C4. CRI also has
binding affinity for iC3b, a cleavage product of C3b. CRI was
first isolated from human erythrocytes, and was shown to be of
205,000 to 250,000 molecular weight on 50S-PAGE. It is an
integral membrane single chain glycoprotein found on a wide
range of cells which
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inclUdes erythrocytes,
monocytes/macrophages, neutrophils, B lympJlocytes and some T
lymphocytes (Fearon and Wong, 19B3). Low concentrations of
soluble CRl are also present ...n plasma ('{oon and Fearon,
1985). The number of receptors varies among cell types, with
peripheral blood neutrophils, monocytes, and B lymphocytes
having 20,000-40,000 CRI/cell, T lymphocytes having one-tenth
this number and erythrocytes having an average of only 100-
1,000 CRI/cell (Fearon, 1980; Wilson et a1., 1983).
The ontogeny of CR1 on human B lymphocytes has been studied
(Tedder et a1., 1983). The receptor is present on only 15\ of
large pre-B cells and 35-50\ of small pre-B cells in the bone
marrow. Although 60-80\ of immature B cells in bono marrow and
fetal liver and all peripheral blood mature B cells express
CRl, maturation to plasma cells is ilssociatcd with the loss of
CRl.
2.6.2. Genetics
Although initial investigations had suggested that CRl WilS
a single chain polypeptide, later studies tound some variation
in the size of CRl isolated from different individuals. It is
now known to be a polymorphic protein with four allotypes that
differ in molecular wp.ight but do not differ in their capacity
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to bind C3b/C4b. The common allotype, A, ith II gene frequency
of 0.82, has a tDoleculllr .ass of 190 kOa hile the B allotyPe,
with II gene frequency of 0.18, appears to be 220 kDa. Rare CRI
al10types C and 0 have a higher, 250 kDa and II lower, 160 kDa
molecular weight, respectivelY (Dykman et al., 198), 1984,
1985: Wong et al., 1983; van Dyne et al., 1987). The basis for
the large difference in molecular mass bet....een the allotypes
....as shown to be a protein difference rather than a difference
in glycosylation, and later genetic studies sho....ed that it was
due to duplication of homologous domains (Wong et aI., 1986,
1989) .
The primary sequence of the A allotype of CRI has been
deduced from the eDNA. sequence and includes a 41-residue
signal peptide, an extracellular dorn.ain of 1930 residues, & 25
amino acid transmembrane domain, and a 43 amino acid
cytoplasmic rcqion (Klickstein et al., 1981, 1988). The
extracellular domain includes thirty short consensus repeats
(SCRs) sim.ilar to those present in other C)b/C4b binding
complement proteins. As shown in Fig. 2.2, the 5' 28 SeRs of
CRI are organized into four tandem long homologous repeats
(I.JiR) termed U1R-A., -8, -c and -0, 5' to 3', respectively.
(Note, the UlR terminology A, B, e and 0 does not correlate
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Figure 2.2. Schematic representation at human CRl and CR2. Boxes, short consensus
repeats (SeRs), some comprising long homologous repeats (LHR); -, ligand
binding sites (such as C3b. C3d) or epitopes (such as HB-5). TM·CYTO, transmembrane
and cytopiasmic domains;
vith the allotypes A, 8, C and D.) Each contains seven SCRa
encoding about 450 amino acidS, and the sequence homology
a.ong the corresponding SCRs in each W9. ranges from 60\ to
99\. Distinct binding sites for C3b and C4b in LHR-A, -8 and -
C have been dellonstrated by analysis of the formation ot
rosettes betveen the COS transfected CRI mutants and C3b- or
C4b-coated sheep erythrocytes, indicating that a LHR
represents a structural and a functional unit. TW'o distinct
ligilnd binding sites for C3b were found to reside in LHR-B and
-C, respectively, and an additional binding site for C4b ",as
located in lJIR-A. U1R-D had no C3b or C4b binding function.
The allotypic differences in size by incr@ll\ents of 30 Kda
may be accounted for by the variable numbers ot LHRs. Direct
evidence in support of this proposal was obtained by isolating
and mapping overlapping phage and cosllid clones frail a genollic
library prepared vith DNA from an individual ho.ologous for
the B allele (Wong et a1., 1989). It was found that t':1e B
allele has an additional genolllic segment which appears to
encode an additional IJfR resembling a chimera of the 3' region
of IJfR-A and the 5' region of HLR-B. This allele most likely
arose through lin hOlllologous recombination event inVOlving the
Um-l\ and -B region, and similar mechanisms of duplication or
deletion by homologous recombination with unequal cross-over
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may account for the other t ....o rare CRl allotypes. Thus, the
smallest allotype C ....ould contain J LHRs while the largest
allotype D would contain 6 LHRs.
The CRl polymorphism was also observed at the transcription
level (Wong et al., 1986; Holers et a1., 1987). The
individuals expressing the various CRl phenotypes had
incremental differences of about 1.4 kb in mRNA. This
difference corresponded to the size of one LHR and the 30 kDa
differences seen among allotypes of CR1, further sugqcsting
that intragenic duplication or deletion of the LHR rather than
alternative mRNA splicing formed the basis for the structural
polymorphism.
The number of CRl molecules on erythrocytes can be qu i te
different from one individual to another (wilson et al.,
1982). In addition to an allotypic variation in the size of
CR1, the number of CR1 per erythrocyte (CRI/E) is also a
heritable trait. 11. restriction fragment length polymorphism
(RFLP) that correlates with either law or high numbers of
CRI/E has been identified in the CRI gene using Hind III
(Rodriguez de Cordoba and RUbinstein, 1986; Wilson et al .•
1986; Wong et al., 1989)_ Individuals may cxpreGG either vary
low numbers of CR1/E (6.9 kb Hind III fragment), high numbers
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of CR1/E (7.4 kb fragment), or have intermediate numbers of
CR1/E ( heterozygotes with both 6.9 and 7.4 kb fraq.ments).
Whether this genomic polym.orphislD has direct effects on
transcription or whether it represents Ito mark.er for other
factors awaits the definition of the promoter/enhancer
elements in the CRI gene and a comparative study of their
relative regUlatory capacities in individuals who express high
or loW' CRl nUlIlbers.
The human gene for CRl is linked to the genes for other RCA
proteins at band qJ2 on chromosome 1 (Weis et a1., 1987). No
complete deficiency states for CR1 have been reported but a
d,ecreased number of CR1 is found on erythrocytes, neutrophils,
and B lymphocytes of patients with systeBic lUpus
erytheraatosus (SLE) elida et a1., 1982; Atkinson, 1986; Willian
et a1., 1982, 1986). It was initially proposed that
inheritance of 1m.. numbers of CR1/E might be a risk factor
that contributed to the onset of this autoiJmune disease.
However, further studies suggested that the reduced CR1 levels
found in patients with SLE are acquired and not inherited
(Cohen et al., 1989). Finally, studies of patients with SLE
and their families for the 6.9 kb RFLP associated with low
CRI/E showed no correlation of the RFLP with SLE (Moldenhauer
et al., 1987). Even families with a history of SLE did not
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exhibit an abnormally higher incidence of the low CRljE RFLP
(Tebib et a1., 1989). It is therefore likely that the CRI
reduction observed in SLE patients is
characteristic (Walport and Lachmann, 1988).
2.6.3. Immunological functions
acquired
CRl was the first membrane protein to be characterized as
an inhibitor involved in complement activation. CRl can
regUlate alternative path"'·~y activation by three mechanisms:
impairing uptake of factor B by C3b; displacing Bb from the
C3bBb C3 convertase; and promoting the cleavage of C3b to
iC3b, C3c, and C3dg by factor I. similarly, CR1 inhibits the
classical pathway by impairing uptake of C2 by C4b, displacing
C2a from the C4b2a C3 convertase and from the C4b2a3b C5
convertase, and promoting the cleavage of C4b to C4c and C4d
by factor I (Iida and Nussenzweig, 1981). Despite its ability
to promote the decay of C3 and C5 convertases, CR1, unl ike DAF
and MCP, does not appear to play an essential role in the
protection of erythrocytes from homolor,;ous complement attack
(Medof et a1., 1987). The binding site for CRl on C3b has been
localized to a domain 1n the N-terminus of the u' chain,
spanning residues 727-768 of the C3 sequence (Becheror and
Lambris, 1988). A synthetic peptide spanning this region of
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the C3 a' chain, as well as the corresponding antipeptide
antibody, inhibited CRI binding to C3b and C3c. This region of
C3 has also been shown to be involved in the interaction of
C3b with factor H and factor B (Ganu and Hliller-Eberhard,
1985; Becherer and Lambris, 19881 Becherer et al., 1989).
CRI has important roles as a receptor. The most striking
role of CRI in vivo is to transport complement-coated immune
complexes, and subsequently to enhance clearance of these
immune complexes by the phagocytic system (Cornaceff et al.,
1983; Schifferli et a1., 1986). First, due to the greater
abundance of erythrocytes as compared to leukocytes, immune
complexes that enter or form in the blood bind primarily to
erythrocytes. Second, despite expressing relatively fewer CRl
molecule:J per cell, erythrocytes are able to bind immune
complexes Ilfficiently because their CRI are located in large
clusters on the cell surface. Both soluble and particulate
complement-coated immune complexes can be carried by
erythrocyte CRI to the liver and spleen, Where phagocytic
cells will ingest the immune complexes. This occurs in two
ways: enhancement of tile Fc receptor-mediated phagocytosis of
particles bearing CJb and IgG, and direct phagocytosis of the
C3b-bearing particle mediated by CRl independently of Fc
receptors. Additionally, the therapeutic potential of CRI as
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an inhibitor of cUI~ple'll''ant-mediated inflammatory reactions is
supported by a study in which soluble recombinant CRI reduced
the sizes of myocardial infarcts in a rat model of repcrfuslon
injury (Weisman et al., 1990).
All mature B lymphocytes, a subset of T lymphocytes, and
most antigen-presenting cells express CR1. The involvement of
CR1, ....ell other complement components in
immunoregulation will be reviewed in the next chapter.
2.7. Complement receptor type II (CR2, CD21)
2.7.1. Biochemical features
The cell-surface receptor for the C3 fragments C3dg and C3d
was termed complement receptor type 2, CR2. In 1!}8J, the
receptor was first clearly characterized as a discrete D-
lymphocyte molecule of about 140 kDa (lida at a1., 1983).
Earlier experiments also showed that Epstein-Barr virus (EIW) ,
a human herpesvirus, could bind to CR2, and initiate the
infection of B lymphocytes (Flngeroth et a1., 1984; Nemcrow et
a1., 1985). A recent stUdy further suggested that CR2 may also
function as a receptor for interferon a (Oelci'l:yre et al.,
1991) •
The primary protein structure of CR2 has been determined
through analysis of the nucleotide sequences of clones
isolated from human tonsillar and B lymphoblastold cell line
(Raji) eDNA libraries (Moore at aI., 1987). Four of the five
clones obtained from tonsillar libraries encode a protein
composed of 10J2 amino acids, includinq a 20-amino acid 8iqnal
peptide, a 954-residue extracellular domain, a 24-amino acid
transmembrane region, and a J4-amino acid cytoplasmic domain.
The c)(tracellular domain is composed entirely of 15 short
consensus repeats (SCRs) which are homologous to those found
in other complement CJbjC4b binding proteins. One of the five
clones from the tonsillar library and the single clone from
Raji cells encoded a to'cal of 16 SeRs, with an extra SCR (lOa)
inserted between SeRs 10 and 11 of the 15-SCR form of CR2
(Weis et al., 1988). Recent stUdies strongly suggested that
alternative splicing is responsible for e-'clusion of the lOa
SeR which is encoded by a single exon (Fuj isaku et al., 1989;
'roothaker at al., 1989). CR2 SCRs can be grouped into four
"UlRs-like" domains (I-IV), based on their relative homology
/Pig. 2.2).
Evidenco from biosynthetic and enzymatic approaches
indicate that CR2, which contains N-linked oligosaccharides,
is derived from a 110-120 kDa non-glycosylated precursor with
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potential sites for glycosylation in its extracellular domain
(Weis and Fearon, 1985). Although the half-life of
glycosylated CR2 on the cell membrane is much longer than that
of non-glycosylated CR2, the oligosaccharide residues are not
necessary for CR2 binding to C3d/C3dg. The cytoplasmic domain
contains three serine, two threonine, and four tyrosine
residues, inclUding the sequence -TSQK-. This is the best
candidate for a protein kinase C substrate (Kishimoto et al.,
1985). The cytoplasmic domain of CR2 is too small to encode a
tyrosine kinase, but it is possible that the sequence -EAREVY-
may serve as a substrate for tyrosine phosphorylation (Ilunter
and Cooper, 1985).
Human CR2 has been found on mature B lymphocytes (Iida at
a1., 1983; Weis et aL, 1984), follicular dendritic cells
(Reynes et al., :~~5) and epithelial cells ('{oung ct a1.,
1986: Birkenbach et aI., 1992), thyrnocytes (TsQukas and
l.ambris, 1988) and same T lymphocytes (Sauvageau et al., 1990;
Fischer et aI., 1991). CR2 expression on various cell types or
lymphoblastoid cell lines is quite different from one to
another. For example, tonsillar mononuclear cells express
abou'.; 17,000 CR2 per cell while peripheral mononuclear calls
express 12,000 CR2 per clJ!ll; and th~ Burkitt 8 lymphoma cell
line Raji expresses 24,000-63,000 receptors per cell aEi
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compared with 8,000 receptors per cell for Kolt-4, a T cell
lQukemia line (Fingeroth et al., 1984).
Analysis of CR2 expression during human cell
differentiation, using monoclonal antibodies to CR2, showed
that pre-B and immature B cells from fetal bone morrow and
liver did not express CR2 (Tedder et a1., 1984). CR2
expression is characteristic of the mature B cell, but it is
lost during the differentiation from B cell to plasma cell.
A soluble form of CR2 (sCR2) has been shown to be present
in easily detectable amounts in culture supernatants of B
lymphoblastoid cell lines like Raji, and in normal human serum
(Ling et al., 1991; Ling and Brown, 1992). The tissue source
ilnd function of sCR2 are unknown. It may rE<~resent a
spontaneously shed proteolytic fragment of CR2.
2.7.2. Genetics
The CR2 gene spans 25 kb within the RCA cluster located on
human chromosome 1, band qJ2 (weis et aI., 1987, 1988;
Fuj isaku et al., 1989). The fully processed mRNA is 5 kb (weis
et al., 1986). At the DNA level, CR2 polymorphisms have been
identified by comparison of the DNA sequences of the published
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CR2 clones from different laboratories (Moore et al., 1987;
Weis et al., 1988). As described above, some of these clones
have IS SCRs while others have 16 SCRs. Moreover, both mRNA
forms have been found (Toothaker et al., 1989). Thus, these
data suggest that. alternative !!se of an extra exon encoding
SCR lOa can produce two forms of CR2.
Several allelic forms of CR2 have been identified on the
basis of the existence of restriction fragment length
polymorphisms of genomic DNA (Fujisaku et al., 1989). The Taq
I RFLP involves two bands 2.55 and 2.1 kb. By utilizing more
specific subclones on southern blots of genomic DNA. and cosmid
clones, this polymorphic site is near the single exon encoding
seRs 1 and 2. Family studies indicate that these bands are
allelic. Gene frequencies in Caucasians are 0.1 and 0.3 for
the 2.55 and 2.1 kb fragments, respectively. Similarly, a HilC
III RFLP has also been found. There are three bands of 1.75,
1.55 and 1.45 kb at gene frequencies of 0.02, 0.05 and 0.93,
respectively, in caucasians.
Unlike other proteins encoded by the RCA gene cl ustcr, CR2
pOlymorphism at the protein level has not yet been reported.
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2.7.). IDlJIIunological functions
The functions of CRl have been lIore difficult to define
than those of other C3b/C4b binding proteins. It is known that
CR2 is a membrane regUlatory, ·-"')tein of complement activation,
and that CR2 serves as a receptor on 8 cells for both C3d
fragments, and EBY (Flngeroth et aI., 1984: Hemerow et aI.,
1985). It has also been implicated in the modulation of i1l\)llune
rcsponses although the mcchanisms by which this occurs are not
well understood. Other biological roles for CR2 have recently
been postulated. CR2 may act as an interteron-a receptor
(Oelcayre et al., 1991) and CR2 on T lymphocytes may mediate
infection by human immunodeficiency virus (HIV) independently
of C04, the well~defined HIV target on T t'lelper cells (Boyer
et a1., 1991.1992; Hontefiori et a1., 1992), Finally, CR2 has
also been identified as the ligand for the soluble C02) (Aubry
et aI., 1992).
CR2 regulates the complement cascade by servinq as a
cofactor for factor I-mediated cleavage of membrane-bound CJb
into iC3d (Kinoshita et al., 1990), and into CJc and CJl.lg
(Mitomo at aI., 1987). As this cofactor activity was blocked
by CR2-specific monoclonal antibodies, it was concluded that
CR2 rather than CRI was responsible for the effect.
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The binding site on C3d for CR2 was initially identified
within a 8,600 dalton CHBr fragment of C3d, and then more
precisely localized, by a series of overlapping synthetic
peptides, to residues 1209-1236 of the CJ sequence (Lambris et
a1., 1985). This region is sandwiched within the discontinuous
factor H binding site (Lambris et a1., 1988) and may yield a
plausible explanation for the factor H-like cofactor activity
of CR2 (Mitomo et a1., 1987). Also, this region is similar to
a sequence of the gp3S0/220 glycoprotein of EBV at residues
21-31, suggesting that EBV may bind to CR2 via the 21-31
sequence (Nemerow et ai., 1987). Synthetic peptides from this
sequence of gp3S0/220 bind to CR2 and compete with CR2-bindinq
peptides derived from C3d (Nemerow et al., 1989). Furth<>rt:lore,
the CR2 specific monoclonal antibody OKB-7 inhibits both C3d
and EBV binding to CR2 (Nemerow ct al., 1965), and a deletion
mutant of gp350/220, missing two amino acids from the region
of similarity with CJd, does not bind CR2 (Tanner et 01.,
1988). In contrast, data obtained using CR2-specific
monoclonal antibodies and an anti-idiotypic anti-CRZ antibody
indicated different binding sites on CR2 for CJd and gp350/220
(Barel et a1., 1988). Recent studies have provided a
conclusive answer to this question. A series of transfectants
of truncated CR2 mutants were used to map the epi topes on CR2
for C3d, EBV, and CR2-specific monoclonal antibodies. The CJd,
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EBV and anti-CR2 mAb OKB-7 binding sites are found in the two
amino-tenlinal SCRs of CR2. SCAs 3-4 express an epitope for
anti-CR2 mAb HB-S while SCRs 9-14 express an epitope for anti-
CR2 aAb 82 (Lowell et al .• 1989: Carel et al., 1990). The
intracytoplasmic domain of CR2 is not required for binding of
C3d or EBV but is necessary for internalization of cross-
linked C3d as well as EBV infection of cells (Carel et aI..
1990) .
EBV is an oncogenic herpesvirus which causes acute
infectious mononucleosis, and is implicated in the
pathogenesis ot Burkitt's lymphoma, nasopharyngeal carcinoma
(Tosato, 1987), and some autoilllmune diseases such as
rheumatoid arthritis (Roudier et aI., 1989). It is capable ot
infecting and i.mortal1zing human B lymphocytes .in........Y.J..
Experiments have shown that EBV infection is mediated by
gp350/220 binding to CR2 on B cells (Tanner et aI., 1987;
Nellerow et al., 1987). Although CR2 can bind EBV it has not
been deterllined whether cellular expression of CR2 is
sufficient for infection. This question was addressed in part
by stably transfccting: murine L cells with a fUll-length human
CR2 cDNA (Cantaloube et al., 1990). Transtectants expressed
high levels of CR2 and specificallY bound both C3d and EBV.
Coculture of these cells with EBV led to infection of
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approximately 0.5% of the cells, as assessed by staining for
Epstein-Barr nuclear antigen (EBNA). The low eff iciency of
infection compared with human B cell lines may indicate that
additional factors are involved in deternining EBV tropisllI.
with regard to virus infection, recent studies have led to the
conclusion that CR2 mediates human illllnunodeficiency virus typo
I infection of a human T cell line in a cD4-indcpendent
fashion (Boyer et al., 1991, 1992; Montefiori et al., 19921.
CD4 is believed to be the primary receptor for HIV on human T
cells. The presence of CR2 on T calls and other target cells
may thus be critical for massive infection in normal
individuals, and for viral propagation in infected patients
(Tosoukas and Lambris, 1993).
surprisingly, computer analysis of the secondary structure
indicated that interferon Q (INF-ct) also contains a sequence
motif similar to the CR2-binding site of CJd (Delcayre et al.,
1991). Experiments have shown that antibodies against a
peptide with the CR2 binding sequence of CJd react with a
peptide carrying the IFN-Q CR2 binding motif (residues 92-99).
This motif is conserved in most IFN-a SUbtypes. The. IFN-ct
derived peptide, as well as recombinant IFN-a, inhibits CJd
interaction w-ith CR2 on Raji cells. Direct interaction of IFN"
a with CR2 is inhibited by polyclonal anti-INP-a, anti-CR2 and
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anti-CJd peptide antibodies as well as Cll:!. qpl50/220 ot EBV
but not by interteron-y (I:FN-y). And .tinally, If'N-Q binding to
Raji cells can be blocked by anti-CR2 monoclonal antibody HB-S
but not Ol<B-7. A.s "entioned above, HB-S can block neither the
binding of C3d nor gpl50/220 to CR2. Thus. CR2 lIay have a
distinct site tor the IFN-o binding. It is likely that CR2
possesses .ultiple sites of interactions. one for both C3d
fragments and gp350j220 of EBV. and one for INF-o. Such a
model would be analogous to the CRI interaction with C3b and
C4b.
CR2 is postulated to play a functional role in B cell
activation and differentiation (Cooper et al., 1988; Ahearn
and Fearon, 1989). The nature of the ligand interacting with
CR2 appears i.portant since Jlonovalent fluid-phase C3d
frag.ents generally inhibit~ B cell responses while
lIlul tivalent CR2 ligands have been shown to induce qro\tlt.h and
di fferentiation ot B cells. Our current knoWledge of the
regulation of illlmune responses by cOlllple.ent components
inclUding CR2 will be detailed in the next chapter.
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2.8. Murine complement receptor family
The existence of mouse complement receptors that are
functional hl'lIIoloqs of human CRl and CR2 was inferred long
ago. Sheep erythrocytes bearing mouse or human CJb form
rosettes with mouse spleen cells and macrophages. An immune
adherence and immune complex clearance mechanism, similar to
the human CRl mechanism, exists in mice, although complement-
coated complexes bind to mouse platelets rather than
erythrocytes (Kinoshita et al., 1985).
Recent studies have demonstrated three CJ-binding proteins
in mice (Kinoshita el:. aL, 1985; Wong and Fearon, 1985). 'rhese
have been designated p190 (mouse CR1) , p150 (mouse CR2), and
p65. Interestingly, when mAbs were raised to the mouse p190,
two of the three mAbs also recognized the mouse p150
(Kinoshita et al., 1988). These data suggested that the two
mouse complement receptors are closely related to each other
antigenically, and perhaps structurally. Surprisingly, despite
extensive searches, no OAF or MCP genes have been discovered
in mice (Krych et al., 1992).
It is now known that unlike the human system, in Which CR1
and CR2 are independent gene product~, the p190 is the product
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of alternative splicing within the mouse CR2 gene (Kurtz et
al., 1990: Molina et al., 1990). The plS0 (.ouse CR2) 1_
highly hOllOloqou& to human CR2 (Kurtz et al., 1989; Fingeroth,
1990). These conclusions ...ere pri.arily drawn from studies of
recombinant transfectant cells. There are two transcripts tro.
a common gene. One transcript encodes 15 SCRs with elCon-intron
junctions identical to human CR2. The second transcript
encodes 21 SCRs and is generated by the addition of six extra
SCRs \:.0 the .first CR2 SCR. The recombinant 15 SCR form, rMCR2,
has been expressed in the human erythroleukemia cell line
K562. The transfected cells express alSO kDa protein that is
identical in size and function to the natural mouse CR2
(Molina et al., 1991). Cells transfected with the recombinant
21 SCR, rMCRI, yielded a 190 kDa protein that reacts with a
Jaonospecitic anti-mouse CRI 1I'lAbs as well as anti-CR2 tlAbs.
This 21-SCR containing rHCRI moleCUle also binds CJb as well
as C3dg (Kolina et aI., 1992). Therefore, it is believed that
mouse CRI and CR2 arise by alternative splicing froll a COUOh
gcme. In Fig. 2.3 is shown a schematic representation of the
two receptors along with p65, a gene product apparently unique
to the lllOuse. The p6:· gene, designated crry, contains five
SCRs with signit'icant sequence identity to SeRs 1-6 ot MCRlo
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Figure 2.3. Schematic representation of mouse homologu6s of human
complement receptors. MCR1 is the product of an alternatively spliced mRNA
derived from the MCR2 gene. Crry/p65 is an intrinsic complement regulatory
protein. \'Jhose five SeRs are significan~lyhomolo]ous to human CR1. TM-CYTO,
transm=mbrans and cytoplasmic dorr,ains.
2.9. superfamily ot Short Consensus Repeats (SCRs)
As discussed earlier, the requlators of complement
activation include six proteins: factor H, C4BP, OAF, MCP,
CR~, and CR2. One or the common features at the six proteins
is a conserved motif of approximatelY 60 !llIino !:odds, ~hich is
characterized by having a framework of four invariant
cysteines (disulfide-bonded within each motif in the manner 1-
J, 2-4) and several other highly conserved residues inclUding
proline, tryptophan, tyros!ne/phenylllilanine and glycine. This
structural feature was designated as short consensus repeat
(SCR) (Reid, ~986; Klickstein et al., ~987). ThUS, the RCA
proteins "ro related structurally aft well as functionally. The
first evidence that the RCA proteins might have a common
evolutionary origin ca.e fro. linkage studies ot polymorphic
variants of CR1, factor H, and C4BP (Rodriguez de Cordoba at
al., 1985). CR2, OAF and Kep were then added to the list of
lIlembers of the RCA family (Ray-Campos et a1., 1987; Carroll et
al., 1988; Bora et al., 1989). Now, genetic mappIng by pulse
field gel electrophoresis (PFGE) and t.hll yeast artificial
chromosome ('lAC) technique has shown that the genes for CRt,
CR2, OAF, MCP and C4BP are all located in band q32 of the long
arm of human chromosome 1. This region of about 900 kb encodes
six RCA genes and three gene-like elements (pseudogenes) in
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the order (5' to 3') of C4BP-,B, C4BP-a, C4BP-like, OAF, LR2,
CRl, HCP-like, CRl-like and HCP (Ray-Campos et a1.. 1987:
Carroll et a1., 1988: Bora et a1., 1989: Pardo-Manuel et a1.,
1990; Hourcade et a1., 1992). The gene for factor H, though
belonging to this clust:.er, is about 500 k.b a....ay (Fig. 2.4).
In addition to being present in the cOloplement control
proteins, SCRs !ore also found in C2, factor B, C1r/Cls, C6 and
C7 (Hourcade et al., 1989; Reid and Day, 1989). All of these
proteins can bind to C3 or C3b, or to its homologs C4 and C5.
Intriguingly, a number of non-complement proteins have been
shown to contain SCRs, such as human 132-g1ycoprotein, IL-2
receptor, the blood clotting factor XrIIb subunit,
haptoglobin, the core protein from cartilage proteoglycan, and
thyroid peroxidase. Furthermore, SCRs have been identified in
a recently described family of cell adhesion proteins, which
are involved in the targeting of White blood cells to
appropriate sites. These proteins include the endothelial
leUkocyte adhesion molecule I (ELAM-I), the mouse lymph node
homing receptor and the 140-kDa granule membrane protein (Reid
and Day, 1989).
The C3b/C4b binding proteins are now seen as a new family
derived from a common ancestral SCR-encod ... 'lg genet ie element.
Human chromosome 1
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Figure 2.4. Organization of the genes within the human RCA cluster
The evolutionary mechanisms apparently involved exon split,
gene duplication (intra and extra), and alternative
polyadenylation (Hourcade et ~l., 1989).
To better understand the protein-protein recognition role
of the SCR, several lov-resolution structure determination
techniques have been applied. These include low-angle X-ray
and neutron scattering of C4BP and factor H (Parkins ct aI.,
1986, 1991), and electron microscopy of C4BP, recombinant CIU
and recombinant CR2 (Dahlback et aI., 198J; weisman at a1..
1990; Moore et aI., 1989). These studies led to the proposal
of a structure of "j3-sheet-sandwich-type" model for the SCR.
Recently. the two- and three-dimens ional structure, bilGed
primarily on nuclear magnetic resonance data of one SCR,
namely the 16th SCR from human factor H, has been described
(Barlow et al., 1991; Norman et al., 1991). It features j3-
strands with interspersed turns and loops. One face of the SCR
is formed by a triple-stranded j3-sheet and the other (ilce by
two segments of double-stranded antiparallel j3-sheets. A larqe
compact core is composed of h::'ghly conserved hydropho dc amino
acids, consistent with their expected structural role. 1'he
carboxyl ",nd amino termini are at the opposite ends of the
unit, which is J.8 nm long. It has been proposed that the
structure of other SCR is 'Iery similar, with the conserved
(,5
residues providing the structural framework for variable amino
acids. These variable residues could be involved in specific
interactions in much the same way as the different
immunoglobulin (Ig) domains can fulfil a varied number of
binding and functional roles (Reid and Day, 1989).
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CHAPTER 3
COMPLEMENT AND IMMUNE RESPONSES
3.1. Early studies
Since the early 1970s it has become increasingly apparent
that proteins of the complement system can influence different
stages of the immune response. But, the mechani,sms by which
complement regulates immu.,e responses remain to be clarified.
The first experimental evidence for the role of complement
in thymus-dependent antibody production~ came from
experiments where mouse C3 was depleted with cobra venom
factor (CVF) (Pepys, 1972, 1974). CVF does not affect the
total number of cells in the spleer, or lymph nodes, the
proportions of cells with different surface markers inclUding
Ig, Fc receptors, and C3 receptors, or the functional capac Jty
of the different cell populations. T cells in CVJ<'-trcated
animals respond normally to thymus-dependent antigens. But,
antibody response in these mice was depressed (Pepys at a 1. ,
1976). It was subsequently found that CVF treatment also
completely inhibits follicular localization of antigen-
antibody complexes. However. once immune complexes have become
localized on the surface of dendritic cells in the germinal
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centres (GC).~ depletion of complement by CVF does not
dislodge them (Papalllichail et alo. 1975). In contrast. the
induction of tolerance to thymus-dependent antigens and
thymus-independent antigens is unaffected by CVF (Pepys and
Taussig et alo. 1974). Th!lS. if complement does playa role in
the induction of antibody production. it is likely that the
complement component CJ and the receptors for C3 on
lymphocytic cells are involved.
Th~se specula tions have been strengthened by studies of
genetic deficiency models. Individuals genetically deficient
in specific complement components allow the role of complement
in the induction of immune responses to be addressed directly
.in....Y.i.Y2. without the disadvantages of decomplementation. They
also allow the classical and alternative pathW'ays of
complement activation to be differentiated. It W'as found that
the absence of CJ C"''': -c.he components of the classical pathway
C3 convertase seriously impaired bllllune responses. This has
been clearly shown in cases of genetic deficiencies in C2
(Bottger et al., 1985), CJ (O'Neil et al., 1988) and C4
(Jackson et al., 1979; OChs et alo, 1983) described in humans.
guinea-pigs, and dogs. In contrast, humans or animals with
deficiencies of CS, C6 and C7 usually have normal immune
responses (Martinelli et al., 1978; Ochs et al .• 1986).
3.2. CUrrent knowlt: ,ge
In recent years, al though possible modulatory functions of
Clq, Ba, Bb, and CSa in immune responses have also been
suggested, the bulk of experiments have dealt with the
immuno.cegulatory role of C3 and its cleavage products (Erdei
et aI., 1991). It now appears that C3 is necessary both to
mount normal antibody responses and for the induction of
immunOlogical memory (Bottger and Bitter-suermann, 1987). The
effects of C2 and C4 deficiency in terms of immunoregulation
may be a reflection of the lack of C3 activation. There are
good reasons to believe that C3 is more important thiln other
complement proteins. First, C3 is the most abundant complement
protein in serum and other body fluids. Second, C3 plays a
pivotal role in both the classical and alternative pathways.
Third, when activated, C3 will be split into a variety of
smaller fragments such as C3b, iC3b, C3dg. These fragments can
bind to Ag-Ab complexes and/or interact with their
corresponding receptors present on the surfaces of different
cells. The effects of these interactions have a diverse
spectrum of consequences, depending upon the types of
receptors and cells involved. It has been found that there are
at least four types of receptors for C3-derived fragments
(shown in Table 1.1). CRJ a. : CR4 are mainly involved in cell-
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cell adhesion, or the clearance of immunp. complexes by
phagocytic cells (Sim et al.. 1987; Becherer et al., 1989).
Studies on the iltllTlunoregulatory capacity of CRI and CR2 have
attracted much attention in the past decade.
Although CRI is found on cells involved in the iltllTlune
response, L.h on all 8 cells, some T cells and most antigen-
presenting cells, its regulatory effects on the immune
response arc controversial. Possibly these effects are exerted
in an indirect way. Stimulation of human monocytes with CJb
induces the production and release of JL-l. (Bacle et al.,
1990). JL-l is mitogenic for T cells that express specific
receptors for this lymphokine and it stimulates B cell growth.
Direct cross-linking of CRI on human B cells does not induce
a proliferative or differentiation response, nor does it cause
the release of intracellular calcium. However, a signal may be
presumed to occur since cross-linking of CRI does lead to co-
capping betw£en CRI and surface immunoglobulin (Tsokos et al.,
1988). Perhaps more relevant to its effects on immune
responses in vivo are the findings of enhancement of antibody
production~ by pre-activated B cells in the presence
of polyclonal anti-CRI antibodies. This eftect was not
observed consistently when a monoclonal anti-CRl antibody was
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used (Tedder at a1.. 1986). The function of CRl on T cells is
largely unknown.
Data are accumulating about the regulation of immune
responses by complement receptor type 2 (CR2). For instance,
CR2 serves as a receptor on human B cells for mitogenic EBV
which can transform B cells from the resting stoige to a
lymphoblastoid phase (Tosato, 1987). calcium mobilization
could be induced by EBV binding, and this effect was also
accompanied by protein kinase C translocation as well as by an
increase in production of phosphat idyl inositol metabolites
(Dugas et a1., 1988). Lipopolysaccharide-activated murine B
cells proliferate and mature into immunoglobulin-secreting
cells after exposure to insoluble multimeric forms of C3d
(Mclchers et al., 1985). Certain mcncel-mal and polyc1ona1
antibodies to CR2 also induce B cell proliferation and Ig
secretion in the presence of T cells or T cell tdctors
(Mittler et a1., 1983; Nemerow et a1.. 1985) _ C3dq fragments
or tIlultivalellt synthetic peptides corresponding to the CR2-
binding site on C3d support growth of human CR2-poliitive
lymphoblastoid B celJ. lines (Hatzfeld et al., 1988; Servis 'lind
Lambris, 1989; Tsokos et al., 1990; Lyamani et al .• 1991).
Furthermore, synergistic interaction between CR2 and sIgM on
B £.:ells inc>:eases the free intracellular calcium concentration
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(Carter et al., 1988). This observation indicates that
although the cytoplasmic domain of CR2 itself is too short,
ligating of CR2 on B cells can deliver atiaulatory signals
through sIgH. Taken together, these data suggest that C3d and
CR2 are likely the key complement components of importance in
the iJQDIune response.
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CHAPTER ..
AIMS AND OBJECTIVES
wi th the advent of modern techniques such as DNA
recombination and monoclonal antibody methodology, much
progress has been made in the area of complement research.
Current interest is focused in three major areas: 1)
regulation of complement activation, 2) mechanisms of host
cell protection, and 3) roles of complement and complement
receptors in the immune response.
This project initially began with studies on genetic
polymorph isms of the regulators of complement activation.
Later, tha objective was expanded to evaluate the
immunological functions of complement receptors, especially
the CR2 molecule, in the immune response.
Therefore, the particular aims of the studies reported in
this thesis have been:
1) To simplify the procedure for typing complement (actor n,
and technicallY improve the reliability of the prnceoure.
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2) To exalline the distribution of variants of factor H in
people with autoimmune diseases such as rheUlllatoid
arthritis.
3) To estimate factor I allele frequencies in a Caucasian
population, and to compare the data with those obtained
in Asiatic populations.
4) To identify polymorphism of complement receptor type
2 (CR2) at the protein level.
5) To characterize the binding epitopes of CR2 variants by
flow cytometry.
6) To establish an animal model for evaluation of CR2
function in primary and secondary antibody responses.
7) To compare illUlunosuppression induced by cobra venom
factor (CVF) with that induced by anti-CR2 lIonoclonal
antibodies.
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CHAPTER 5
MATERIALS AND METHODS
5.1. P"Ictor H typing
5.1.1. Blood samples
Blood was collected from family members or single
individuals in the local community, by venipuncture into
Vacutainer tubes (Becton Dickinson, Rutherford, NJ., USA).
Sera were separated, labelled, and stored at -70·C. Samples
from patients with rheumatoid arthritis were collected by Dr.
Martin at the Rheumatic Disease unit, St. John's. All patients
met the American Rheumatology Association (ARA) criteria for
classical or definite rheumatoid arthritis (Ropes et aL,
1958) •
Whenever a sample was used, it was thawed quickly in a 37'C
waterbath, kept on ice while being used, and thereafter
refrozen as soon as possible.
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5.1.2. uetec:tion of fnctor H phenotypes
Isoelectric focusing was carried out according to the
methods of Rodriqu(:i: de Cordoba and RUbinstein (1984), with
the modification that factor H not
immunoprecipitated prior to focusing. A vertical slab
polyacrylamide gel (160 X 1600 X 1 rom) containing 1. 7t NP-40
(Sigma, st. Louis, MO., USA), 8 M urea (Bio-Rad (Canada),
Mississauga. Ont., Canada), 2' ampho1ine (LKS, Piscataway,
NJ., USA) mixture (pH 3.5-10 : 4-6 : 5-8 .. 1 : 4 : 4) was
used. 5 ul of serum pre-treated with neuraminidase were
applied to each slot (10 u1 of serum was incubated at room
temperature o-/erni.ght with 1 U of neuraminidase type V,
Sigma). 0.01 M NaOH (Fisher Scientific Ltd., Montreal, Que.,
Canada) and 0.01 M H,PO, (BDH Canada Ltd., Toronto, Ont.,
C<:Inada) used cathode and anode solutions,
respectively, and isoelectric focusing was conducted on a
PROTEIN II apparatus (Bio-Rad) with 400 V overnight. The
proteins were then electroblotted onto a nitroce ... lulose
membrane according to the instructions of the manUfacturer
(Ilio-Rad). The factor H protein was detected utiing goat-anti-
human factor H (1i'1H) (at 1:300 dilution; At1anti('" antibodies,
ME., USA) followed by peroxidase-conjugated rabbit anti-goat
IgG (at 1: 600 uJ.1ution; Atlantic antibodies). The protein
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bands were developed with 3,3 '-diaminobenzidine (Sigma) and
H20 2 (sigma) as substrates.
5.2. Factor I typing
5.2.1. Blood samples
Blood was collected from people from the local community.
A small number of samples ....ere collected specifically from
Chinese individuals living in the St. John's area. Sera ....ere
separated, lab~lled, and stored at -70·C. Whenever a sample
was used, it was thawed quickly in a 37"C ....aterb<lth, kept in
ice while being used, and thereafter refrozen as soon as
possible.
5.2.;>. Detection of factor I variants
A horizontal, ultra thin-layer polyacrylamide slnb gel,
previously described by Nakamura and Abe (1985), was used for
factor I typing, with a slight modification, .L..Q.... il mixture of
ampholine (LKB) pH 3.5-10 and pH 5-8 in a ratio of 1:7. ....as
used instead of pH 3.5-9.5 alone. Isoelectric focusing was
performed Iofith a LKB 2103 POlofer Supply on a Pharmacia Flatbed
Apparatus electrophoresis unit (Pharmacia, Uppsala, S....eden).
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For each slab gel, a paper strip was placed at each end. One
strip war: wetted ~ith 1.0 M HJ P04 (anode) and another with 1.0
H NaOH (cdthode). At first, the gel was prefocUsp.d at 4UO V
tor 30 lIlin without samples. Then the samples, which had been
trea-c.ed ,with neuraminidase as described for factor H typing,
were applied to the gel surface with Whatman 3 HM filter paper
(Fisher) at a distance of 1. 0 cm from the anode end. The gel
W,:lS focused at 800 v for 1 h, then the sample application
pieces were removed. The focusing ....as continued at I, 000 V for
3 h. The proteins were electroblotted onto a nitrocellulose
membrane. To detect factor I patterns, two identically
reacting anti-human factor I antisera, rai.sed in goat or sheep
respectively (Wako Pure Chemical Industries, Osaka, Jap"n; lCN
Biochemic'lls, Costa Mesa, <.:A., USA), were employed. The bands
were visualized with a second enzyme-labelled antlbod'y and
enzyme substrates, 3,3 I -diaminobenzidine and H20 2,
5.3. CR2 typing
CR2 is a membrane receptor expressed on B lymphoblilstoid
cells, as ....ell as on peripheral mature B lymphocytes. Since B
cell lines usually express more CR2 than peripheral B cells,
B cell lines were the first choie£.' for CR2 typing. Healthy,
growing B cell lines were radioactively labelled .... ith 1251 , and
,.
th::n t.he illlmunoprecipit.ates of cell lysates wer~ sUbjected to
50S polyacrylamide qel electrophoresis (50S-PAGE). A flo....
diagraJi of these procedures is shown in ~ig. 5.1.
5.3.1. Cell lines
B lymphoblastoid call lines were establ ished from
pQripheral B lymphocytes transformed with Epstein-Barr virus.
In brief, .p~ripheral mononuclear cells were prepared from
heparinized blood by density centrifugation over Ficoll-
lIypaque (Lymphoprep, Cedarlane, Hornby, ont •• Canada). T
lymphocytes were removed by cytotoxic treatment with Lympho-
Kwik (One Lalllbda, Los Angeles, CA., USA). Afterwards, the
enriched B lymphocytes were first infected with an
appropriately diluted culture supernatant of B95-8 (a
transforming strain of EBV) , then dispensed (200 ul per well)
to a 96-we11 flat-bottom tissue culture plate (Nunc, CON Life
Technologies, Burlington, Ont., Canada). After 1-2 weeks of
culture at 37'C in a COz incubator, immortalized B cells were
transferred t., a 24-well plat.e (Nunc), and finally expanded in
a small flask (50 ml) (FALCON, Becton DiCkinson). Later, B
cell lines th".t were growing well were frozen and stored in
liquid nitrogen. The cells could be recovered by thawing
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Radioactively label cells
j
Lyse cells in non-ionic or weakly ionic detergent
1
Pre~clear lysate
1
Add antibody (mouse)
Add rabbit anti-mouse antibody
Immunoprecipitate with Protein-A beads
j
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1
Elute antibody-antigen complex from beads
Analyse by SDS-PAGE
Figure 5.1. Flow diagram of CR2 immunoprecipitCJlion.
"0
quickly at )7"C and re-culturing in fresh mediull [RPMI 1640,
ICN (see below) 1.
As controls, the CR2-positive B lymphoblastoid cell line
Raj! (a Burkitt's lymphoma cell line) and the T lymphoblastoid
cell line Jurkat were used. Both of these lines were obtained
frolll American Type Culture Collection (ATCC), MD, USA.
5. J. 2. Cell labell ing and immunoprecipitation
Ileal thy cells were allowed to grow to a desired density in
culture medium RPMI 1640 (ICN) containing 100 IU/ml penicillin
(ICN), 100 ug/ml streptolllycin (ICN) , 2 mM L-glutamine (ICN)
and lOt v/v heat inactivated fetal calf serum (FCS) (ICN). The
cells were harvested by centrifugatiof" and ....ashed with ice-
cold PBS (Sodium Phosphate Buffer, pH 7.2-7.4) three times.
The labelling of cell membranes with NallSI (ICN or AlIIersham
Canada Ltd., Oakville, Ont., Canada) was perfonaed in a
fUJllchood by the tODO-Gen method recommendeG by the
manufacturer (Pierce, Rockford, IL., USA). The labelled cells
were washed with ice-cold PBS, and lysed with an appropriate
volume of lysis buffer (10 rnM Trig-Hel (Sigma), pH 7.4, 1
mg/ml BSA (Sigma), It w/v NP-40 (Nonidet P-40) (Sigma), 1 mM
PMSF (phenylmcthlsulphonyl fluoride) (Sigma), 150 mM NaCl
8\
(Fisher). 1 mM EDTA. (diethylenediamine tetraacetic acid) 1
(Sigma). The lysate was centrifuged at 10,000 )( g for 2 min.
and the supernatant used for immediate
iIl\lllunoprecipitation, or was stored at -70'C for experiments
the next day. All manipulations were performed on ice.
Before immunoprecipitation of CR2, the lysate 0'.: each cell
line was pre-c14ared by incubat..ion with normal rabbit serum (5
ul for 200 ul lysate) and subsequent incubation with Protein
A-Beads (Protein-A Agarose or Protein A-Sepharose, Sigma or
Pharmacia), followed by centrifugation. The supernatant was
then immunoprecipitated by adding 10 ug of a specific anti-
human CR2 monoclonal antibody (HB-S). HB-S monoclonal antibody
has been purified by affinity chromatography on a Protein-A
Agarose column (Sigma) from the culture supernatant of its
clone purchased from ATCC. No !'\dditional protein bands were
seen on 50s-PAGE, after staining with Coomassie blue (Sigma).
The reaction of HB-S with the lysate was carried out in icc
for at least 3 h. To ensure maximal precipitation, 11
polyclonal rabbit anti-mouse IgG (BIO/CAN, Mississauga, Ont.,
Canada) was added afterwards, and the incubation continued for
2 h. Finally, SO ul of washed Protein A-beads (Pilarmacia or
sigma) were added and the precipitates, bound to the beads,
were harvested by centrifugation. The precipitates ""ere then
H2
/washed extensively: 11 witl, wash buffer (10 lIM Tris-Hel, pH
1.4, It NP-40. 150 nM HaCI, 111M EDTA, 1 mH PMSF) plus 0.5 M
HaCl; 2) with wash buffer plus o.n 50s; 3) with 10 :mK Trls-
Hel pH 7.4, 0.1\ NP-40. Thus, non-specific, bound proteins
would be washed away. The CR2 precipitates were stripped troll
the beads by adding SO u1 saJllpie buffer [0.08 M Tris, 10\
glycerol (Sigma), 2\ 50s (Bio-Rad), 0.01\ bromophenol blue
(Sigma) and 0.1 H ,B-mercaptoethanol (Siqma)] and boiling for
five minutes. The supernatant was then ready to load onto an
50S-polyacrylamide gel.
5.3.3. CR2 purification
CR2 purification froll labelled lysate was perforc.ed on an
arfinity chrol:latography column using HB-S coupled to agarose
beads (AHi-Gel Hz i_unoaffinity kit, Bio-Rad). The
radioactivity and protein concentration of each fraction (100
ul) were lIeasured by a y counter (Gamma 310 system, Beeman,
FuLlerton, CA., USA) or by a spectrophotometer at 280 n. (00
Series 60, Beckman), and the peak fraction was then subjQcted
to SDS-PACE analysis and autoradiography.
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5.3.4. 50S-PAGE analysis
One dimensional 7.5' SDS-PAGE under reducing condi tions was
employed for analysis ot CR2 variants. The gel was cast
according to the conventional method of Lacmmli (1970). In
brief, the 7.5% sepal'ation gel was set first, and gently
overlaid with water. After polymerization, the 3%: stacking gel
was poured on the top of the separation gel, and the "comb"
was placed into the st;lcking gel, making sure no bubbles were
trapped in the sample wells. When the gel became hard, the
"comb" was removed and the sample wells were washed with
water. The samples were then applied to the wells (20-50 ul
per well). The running buffer (0.025 M Tris, 0.192 M glycine
(Sigma), o. I%: 5DS, pH 8.3) was loaded into the top and bottom
of the electrophoresis apparatus (Protean II or Mini Protoan
II, Bio-Rad). Electrophoresis was conducted until the dye
marker nearly reached the gel bottom. Pre-stdined molecular
weight markers (Blo-Rad) were run on the same gel. After
separation, the gel was removed from the apparatus. and dried.
The ractiolabelled CR2 precipitates
autoradiography.
B4
located by
Characterization of epitopes on CR2 variants by flow
cytollletry
To detine possible changes in specifity associated with CR2
structural variants, the ligand binding of CR2 among the
different B cell lines was analyzed by flow cytometry. These
experiments involved the isolation and biotinylation of EBV
particles, and an EBV binding assl"y under the conditions of
either non-inhibition
antibodies.
inhibition with monoclonal
5.4.1. Isolation and labelling of EBV
The isolation and labell ing of E8V particles were achieved
by following step by step the tlethod described by Nemerow ,
Cooper (1981) and Inghirami et a1. (1988). In brief, marmoset
lymphoma 895-8 culture supernatant containing the vi:-:-us was
collected and cleared of debris by centrifugation at 1,500 X
g for 45 Ilin. virus was separated by two sequential cycles of
pelleting at 100,000 x g at 4"C for 60 min and by SUbsequent
banding in a 5 to )0\ dextran T-IO (Pharmacia) discontinuous
gradient prepared in 0.01 M Tris-HCl, 0.15 M NaCl, pH 7.4. The
single interface layer containing the virus particles was
collected. The particles
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pelleted and suspended in
carbonat.:! buffer [0.05 M carbonate (,?isher), 0.135 M NaCl, pH
8.8). The virus was incubated with dimethyl sulfoxide
containing N-hydroxysuccinimido-biotin (Sigma). Frf!e biotin
was removed by dialysis against PBS (pH 7.4) at 4·C. Aliquots
of biotinylated EBV (50 ul/tube) were stored at -70'C until
5.4.2. Flow cytometry
Flow cytometry analysis was performed on a FACStar PIUB
(Becton Dickinson, Palo Alto, CA., USA). Anti-CR2 monoclonal
antibodies, 01<B-7 (Ortha, Rar itan, NJ., USA), HB-5 (ATCC) and
B2 (Becton Dickinson) or biotin-EBV were used. 105 cells were
incubated with 5 u1 of biotinylated EBV or 5-10 ug of anti-CR2
!nAb for 1 h at 4'C in culture medium RPMI 16.0 with 2't FCS.
The cells were then washed three times in the same medium and
incubated for 1 h at o1'C with fluorescein-isothiocyanated
streptavidin (rITC-Avidin) (Sigma) or with rITC-conjugated
goat anti-mouse IgG and IgM (Becton Dickinson), respectively.
For inhibition tests, there were two kinds of experimental
approaches. First, the cells were pre incubated with 10 ug of
anti-CR2, either OK8-7 or HB-5, and washed before the labelled
E8V was added. Second, prior to addition to the cells, the
labelled EBV was incubated with an excess of monoclonal
86
antibody nA1. 72Al is specific for 9P350/~10 of EBV. (The
clone 72A1 was obli"ined from ATCC, the mAb (IgG,) was purified
on ",n affinity ....:olumn). Tho inhibition of EBV binding
measured after reaction with FITC-avidin (Sigma).
5.5. Characterization of the role of CR2 in immunoregulation
Complement receptors, especially CR2, seem to be key
components of complement involved in immunoregu1ation. To
further define such a function of CR2 ~, an animal
system was established in mice.
5.5.1. Mice
Female BALB/c mice were o~tained from Charles River
Laboratories (Wilmington, MA., USA) and were used at 8-16 wk
of age. .\nimals wer.e maintained in accordance with
institutional recommendations.
5.5.2. Antigen
Purified, divalent F(ab')2 fragments of goat IgG, purchased
from Cappel (West Chester, Pl.., USA), were used as Ag
throughout all the expe_~iments. The F (ab' ) 2 fragments were
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from a goat antiserum specific for the Fc regions of all rat
IgG isotypes. In order to eliminate cross-reaction with murine
Ig, the A9 [F(ab')2] was passed through a mouse serum-agarose
column (Sigma) before use.
5.5.3. Antibodies
Three different rat mAbs, 7G6 (IgGZb)' 7E9 (IgGz.) and se12
(IgGZt ) with specificity for murine CR were used (Kinoshita at
a1., 1988). As previously described (Kinoshita et a1., 1990;
Molina et a1., 1991), 7G6 can completely inhibit the C3d-
mee-iated rosette formation whereas 7E9 can not, and therefore
7GG is functionally defined as an anti-CR2 antibody although
both 7GG and 7E9 also bind to CRI. SCl2 is monospccif ie for
murine CRL As a control mAb, RA3-6e2, a rat IgGZb againat C045
(B220) was used. Like CR2, the B220 molecule is a lineage
marker for pre-mature and mature B cells (Thomas, . :J89).
Purified 7G6, 7E9 and 8C12 were gifts of Dr. Kinoshita (Osaka
university Medical School, Japan) while RAJ-GB2 was purified
on a Protein-A Agarose column (Sigma) from culture supernatant
of its clone, kindly provided by Or. M. Dailey of The
university of Iowa. On 50S-PAGE with r"lducing condition,
purified RA:l-GB2 mAb :~ave only two bands, corresponding to IgG
heavy and light chains.
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5.5.4. Preparation of an illlnune complex fOrlll of 1I.q
As mentioned above, Aq was dival·:mt goat F(abt)z against rat
IgG while monoclonal antibodies used were rat IgG. Therefore,
free AC; ,,:ould lJe converted to a complex fOrJI of Ag if mixed
with either mAb. To obtain maximal amounts of i1rllllune complexes
for injection a precipitation curve was established by mixinq
varyinq amounts of qoat fo'(ab'l z with constant amounts of rat
IgG. The rat IgG had been l~I-labelled by the IODO-GEN method
(Pierce), and separated from non-bound NaI on a Sephadex G-25
(Phi'lrmacia) column. It had a specific activity of 1.2 x 105
cpm/ug. After incubation overnight at 4' C, formed
immunocomplcxes were washed with cold-PBS three times, and
then transferred into fresh tubes for Ileasurement of
radioactivity in a y counter (Beckman) (Fig. 5.2). The
equivalent ratio between Aq and Ab was detenained by assumir.q
that the amount of precipitate is in proportion to the total
immune complexes formed (soluble and Jnsoluble). The immune
complex of Ab-Aq prepared this way was used in all further
experiments. When Aq was required in various doses, a single,
large volume of illlJllunocomplexed Aq was prepared, and then
diluted for immediate use.
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5.!">.5. Protocols for immunization
There were two protocols for immunization.
1) The protocol used for this group of experiments will be
described in detail in RESULTS. Briefly, lIIice were first
treated either with a single injection of 200 ug IIIAb or
pretreated with four injections of 5 ug CVF OV€lr a period of
24 h (for a total of 20 ug CVF). The primary antibody response
in all mice was elidted by tail vein administration of 200 ug
antigen in IFA (incomplete Freund's adjuvant, Sigma) in 0.2 ml
PBS. specific IgM and IgG responses were assayed in individual
lIice by ELISA. at different times. Forty days later, secondary
responses were boosted with an optillal dORe of antigen, 6.25
uq of free }l.g in PBS. This had previously been determined as
a lIIinillla1 requirellent for induction of a secondary response.
Specific IgG production was checked five days later.
2) This protocol had three phase!'!. First, the primary
antibody response was elicited in all the lIice using the same
dose of antigen, .L...e..... 200 ug Ag plus IFA in 0.2 ml PBS were
administrated intravenously in the tail. Second, the primed
mice in randomly divided groups were boosted with decreasing
doses of antigen alone so as to find the minimal requirement
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of antigen for induction of a secondary response. Third, the
antigen was given in different forms (free vs complexed) and
the abil i ty of each Corm to induce a secondary response was
compared. various amounts ot Ag were given to boost the
secondary responses.
5.6. Blood sampling of mice
Blood samples were collected individually by puncturing the
tail vein with a 1/27\ needle (Becton Dickinson). Drop by drop,
up to 100 ul of blood could be obtained from a single mouse at
a time. The frequency of sampling varied between expcrimento
(see RESULTS). Serum was separated and stored at -70·C.
5.7. ELISA
Direct sandwich ELISA was employed for detection of
antibody responses. The method, with slight modifications, was
adopted from a standard procedure, recommended by Kemeni
(1991). Briefly, 96-well plates (U type; ICN) were coated with
Ag solution (lO ug/ml, 50 ul/per well) in 0.1 H bicarbonate
buffer pH 9.6 overnight and then blocked with 0.05t Twaen 20
(Sigma) in PBS, followed by three washes with PBS. All sera
were diluted with Pf}S containing 1% BSA. To each well 100 ul
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of diluted serum was added and incubated' for 1 h at room
temperature. The plates were ....ashed .... ith PBS three times.
Alkaline phosphatase (AP)-labelled anti-mouse 19M (Jl chain
specific) (Cappel) or IgG (Fc, specific) (Cappel) was added,
and the plates ....ere incubated for 1 h at ruom temperature,
followed by three ....ashes. PIP activity was measured by the
modified method of Sorimachi and Yasumura (1986), using 4-
aminoa.,tipyrine (Sigma) as substrate. optical density vas read
on a Sio-Rad microplate reader 3550 at 490 nm. For
quantification of specific IgG, ELISA was performed as above,
with the addition of a set of standard wells. Instead of A9,
a goat anti-mouse 19 antiserum (Sigma, diluted 1/400) ....a:-i used
to coat the standard wells. The standards ....ere purified mouse
IgG (Sigma), diluted to 250, 125, 25, 2.5 and 0.25 nq per
well, or purified mouse 19M (Sigma), diluted to 25, 12.5, 2.5,
0.25 and 0.025 "g per well. The standard curves (semi-log)
were automatically plotted and the IgG or IgM amounts of
samples calculated by the microplate reader's software (Blo-
Rad). All samples and standards were in duplicate. For IgG
SUbtypes, Mouse Typer SUb-Isotyping kit (Bio-Rad) was used as
described by the manufacturer.
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6. statistics
statistical analysis was performed with InStat 1.0 software
(GraphPAD, San Diego, CA., USA).
6.1. Chi-square
The association of phenotypic varianto with diseases were
determined by Fisher's exact test.
6.2. Analysis of variance (ANOVA)
One-way ANOVA was used in experiments where there were more
than two groups of data. It should be stressed here that for
the ELISA datlll obtlllined from the secondary antibody responses,
the mean was the antilog of the mean of the logarithm of the
original variable, since the arithmetic means in this case do
not fit the normal distribution.
6,·3. Student'!"· t test
Student's t test was applied to determine if there was a
difference between the means of two groups of samples.
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CHAPTER'
RESULTS
6.1. Factor H typing
Pbenotypes: Samples from 129 local unrelated healthy
individuals typed by isoelectric focusing of
neuraminidase-treated serum. A representative set ot patterns
in shown in Fig. 6.1. Pattern 1-1 and pattern 2-2 each
contained two major bands in the pH interval 6.S to 7.0. This
was demonstrated by measuring the pH of 1 em-wide gel slices
each eluted W'ith 1 ml distilled W'ater overnight (Fig. 6.2).
The bands of pattern 1-1 are focused at a slightly mace basic
position than those of pattern 2-2. In pattern 1-2 these four
bands appear as doublets, as would result if pattern 1-1 was
superillposed on pattern 2-2. According to these observations,
two forms of factor H, FH 1 and FH 2, W'ould be responsible tor
ti'11 three patterns, both forms coexisting in pattern 1-2. The
patterns are reproducible.
Inheritance and allele frequencies: Co-dominant segregation
of these three forms of factor H was demonstrated in 13
families with 58 children (Table 6.1). No exception was found
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Figure 6.1. Irnrnunoblotting patterns of factor II phcnotypcs
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figure 6.2 The pH gradienl of isoelelnc fOCUSlOg gel for
fador H lyping. Al lhe end of a run lhe gel was sliced, and
lhe pH value for each slice was measured.
'[\lIJ)C 6.1. fI<lctoC" If phenotypes in ]) familiQs with 58 children
P,1rcntal lJumber of ~drcn'sQhgnotypes
phenotypes filmiUes
]-1 x 1-]
1-1 X 1-2
1-1 x 2-2
2-2 x 2-2
2-2 A 1-2
1-2 A ]-?
FII 1-1
16
Fil 1-2
1J
FI-l 2-2
'I'ota.l 13 21
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to the rule for autosomal co-dominant inheritance. No evidence
of null genes was found by studyin9 these 13 families, and no
more then two different forms of factor Il were observod in the
same individuals. These results indicate that there are two
common co-dominant alleles c.c: the factor Il gene locus, FII 1-1
and FH 2-2. Pattern 1-1 is the homozygous FH*l/FH+l; pattern
2-2 is the homozygous FH+2/FH"2; and pattern 1-2 is the
heterozygous FH*1/FH*2. The allelic frequencies of factor II in
Newfoundland were calculated from direct gene counting under
the assumption of absence of a null gene. These frequencies
wp.re as follows: FH*l - 0.597 and FJf*2 '" 0.403. The expected
frequencies of the different phenotypes calculated from these
allele frequencies did not differ from the obser.ved values,
indicating the population studied to be in Hardy-Weinuerq
equilibrium (Table 6.2).
Reliability at this method for factor H typing: Some
Newfoudland samples were also typed blind by Dr. Rodriguez de
Cordoba at New York by his method. The results were
conClusive, confirming that the two methods of typing produced
comparable data.
J()(J
'I'<.IlJI c 6.2. Distribution of phenotypes and gene frequencies of
IUliniln factor II.
I'llcnotypcs Olnicrvcll No. Percentage Expected No. ;(2
t"11 ]-1 50 311. 7 '6
m ]-2 5< 41.9 62
'"
7.-2 25 19.4 2]
'I'otal 12' 100.0 12.
VII~ 1 ~ 0.597 d. f. • 1
fo'/f~ 2
-
0.403 0.10 < P < 0.25
0.347
1.032
0.762
2.141
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Faotor H typing in patients with rboUlll.atoid arthriti8: In
addition to a general population sample, a group of 111
patients with an autoimmune disease, rheumatoid arthritis, was
also typed for factor H. The distributions of factor It
phenotypes in the healthy group and the group of patients are
compared in Table 6.3. The allele frequencies in patients
were: FH.l - 0.566 and FH*2 = 0.432. No association of a
factor H phenotype or variant with the disease was found by
Chi-square analysis. However, there was a significant dccrC!ilse
in heterozygote frequency in the group of patients (X 2 = 5.B,
d.f. "" 1, 0.01 < P < 0.025). The reason for this is not clC!1lr.
6.2. Factor I typing
Factor I phenotypes: polymorphism of factor I was first
demonstrated in Japanese (Nakamura et al., 1985). It was
observed that there were three different common patterns (two
homozygous patterns and one heterozygous pattern). Ilomozygolls
individuals have two major bands and some acidic minor bands,
and heterozygous individuals have the compos ito of two
homozygote types. The three common phenotypes were designatcd
IF B (for more basic pI), IF A (for more acidic pT), and IF
AS, respectively. Family studies supported the hypothcsis that
factor I polymorphism was controlled by autosomal co-dominiJnt
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'I'able 6.3. comparison of factor II phenotypes in healthy
control!J und patients with rheumatoid arthritis
I'hcnotypes Controls
No.
FIl 1-1 50 38.7
54 11.9
1-'11 2-2 25 19.4
'L'otal 129 100. a
PatientsO
No.
42 37.8
37.8
27 24.3
111 100. a
x2 '-" 0.93, d.f. '" 2, P = 0.63
U Xl '" 5.62, d.f. "" 1, 0.01 < P < 0.025
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Mendelian inheritance at a single locus with two common
alleles. These findings were confirmed by later studies,
conducted in the western part of Japan (Nlshimukai et al.,
1986), and among other populations in Eurasia (Yuasa et al.,
1988). Isoelectric focusing and immunoblotting were employed
in all these studies, with slight modifications.
In an initial experiment, six samples were selected for
treatment with neuraminidase for different durations to
the effect of the enzyme on the allotype pattern. As shown in
Fig. 6.3, the one to two-hour treatment and the ovenl ight
treatment at room temperature yielded distinct allotype
patterns for the same samples. Clearly, the positions of bands
(major and minor) after overnight treatment were further
shifted towards the cathode. Although treatment for less th.)n
2 h produced clear bands, for more stable patterns overn ight
treatment was preferred.
A new variant or rae tor I: using this technique, a study
was carried out in a group of 288 unrelated Caucilsi<:ln
individuals living in the St. John's area. A representative
electrofocusing pattern is shown in Fig. 6.4. surprisinglY, no
single individual heterozygous for factor I was found. Later,
one person who is a heterozygous carrier of a new (actor I
HW
Figure 6.3. Factor I patterns after neuraminidase treatment
for different time IJeriods. From left to right, 1-6:
overnight; 7-12: two hours; 13-18: one hour.
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Figure 6.4. A representative picture of the identical factor
I pattern from 286 caucasian individuals.
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variant was found. There were some doubts about the method's
reliability, and all doubts were not dismissed until a panel
of factor I reference samples, kindly provided by Drs.
Nakamura (Tokyo Women's Medical College, Tokyo, Japan) and
'iuasa (Tottori University School of Medicine, 'ionago, Japan),
were included in a parallel study. In addition, 17 serum
samples from Chinese students at Memorial University were
collected for factor I typing. Among these ChinEtse samples
were 7 individuals Who were IF AB heterozygous, as shown in
Fig. 6.5.
The new variant of factor I referred to above was found in
a caucasian. It was confirmed in samples from the mother of
the propositus and two siblings. All presented the same factor
I pattern as that of the propositus (Fig. 6.6). A sample from
the Cather was not available. The finding of a new variant in
this family is further supporting evidence for autosomal
codominant inheritance. The new variant band was focused in a
much more basic region than the common IF B. It was designated
IF B1 at the Vlth complement Genetics Workshop and Conference,
Mainz, Germany, 1989. polymorphic factor I variants all have
the same molecular weight as judged by 50S-PAGE (data not
shown) .
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Figure 6.5. Factor I phenotypes of 17 Chinese sera (lanes 1-
17) and 6 reference samples (18-23). Homozygous IF A type:
lanes 18 and 20; homozygous IF B type: lanes 1-2, 4-5, U-12,
17, 19 and 21; heterozygous IF AB type: lanes 3, 6-7, 13-]6,
22-2).
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The predominant factor gene in the population studied is
IF*B w11.h a frequency of over 0.999. The frequency of the
variant IF*Bl is o.oo~, and IF*A is lacking.
6.3. CR2 typing
Preliminary studies: EBV-transformed human B cells were
surface-labelled with 12'5 I and the membrane CR2 proteins that
were immunoprecipitated by monoch.'l1al anti-CR2 (lllJ-5I, were
analyzed by SOS-PAGE and autoradiogral-t,y. Two refct"€:mce call
lines, the CR2-positive B lymphoma cell line Raji, and the
CR2-negative T lymphoblastoid cell line Jurkat, were used in
a preliminary experiment. As shown in Fig. 6.7,
radiolabelled material was observed in the precipitates of
Jurkat cell lysate. In contrast, the immune precipitate::> frolll
Raji cell lysate yielded a heavy band of radioactivity having
a molecular weight of about 140 kOa. The results were
reproducible.
CR2 from labelled Raji cell lysate was purified on an
affinity chromatography column (p. 83). The autoradiography
band of the eluted CR2 was identical to that of the
nonpurified CR2 immunoprecipitate, as prcsonted in Fig. 6.8.
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t'igurc 6,7, CRI and CR2 immunoprecipitates from Rajl and
Jurk<lt cell lines, Lanes 1 (Jurkat) and 2 (Raj i) , CRI
precipitate by anti-CRI !nAb YZ-l~ lanes J (Jurkat) and 4
(Raj i), CR2 precipitate by antl-CR2 mAb H8-5. Jurkat is
negative for both CRI and CR2.
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Figure 6.8. Purification of CR2 from labelled Raji lysate ('
Protein concentration, • CPM). The inserted picture shows the
50S-PAGE bands of fractions 6 (lane 1) and 7 (lane 2), and of
the unfractionated precipitates (lane J).
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Finally, the immunoprecipitated CR2 was treated with
.neuraminidase. and a cOllparison of treated CR2 with nontreated
CR2 is presented in Fiq. 6.9. Sa.ples from three individuals
were tested, lanes 1-3 being treated and lanes 4-6 being non-
treated samples. As expected, there was only a slight decrease
in molecular weight seen in all three samples after treatment.
Tilken together. these preliminary data indicated that the
method of 50S-PAGE analysis of radialabelled
imrnunoprcc:ipitatcd CR2 was appropriate for CR2 phenotyping,
and the reference cell lines were quite reliable.
CR2 Phenotypes: B cell lines froJ! 63 different individuals
includinq 9 patients with rheumatoid arthritis were analyzed
by SOS-PI.CE. The typical patterns are shown in Fig. 6.10. All
cell lines, except cell line 5, expressed the common CR2
lIlolecule of about 140 kDa. Cell line 5 yielded a band of 75
kOil, alom] with another band (indicated by an arrow in Fig.
6.10). The extra band could represent the heavy chain of
surface illll1unoglobulins based on its molecular weight, or
could be one of the components of the CR2 complex. These
possibilities will be addressed later (p. 170). The cell lines
I, 2 and 7 also had the extra band of 75 kDa as well as the
common CR2.
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Figure 6.9. 50S-PAGE of CR2 after and before treatment with
neuraminidase. Three samples were tested: 1 anes 1-3, tre<ltcd;
lanes 4-6, non-treated. Non-treated CR2 has a mol",cular weight
of approximately 140 x lO} while neuraminidase-treated CR2 hils
a molecular weight of approximately 120 x lO}.
2 3 4 5 6
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Figure 6.10. CR2 polymorphism identified by 50S-PAGE. Lane 5:
CR2 L/L homozygous; lanes 1, 2 and 7: CR2 II/L heterozygous;
lanes 3, 4 and 6: CR2 H/H homozygous.
m~. 2 3 4 5 6 7
X103
123
-
These patterns could be interpreted as follows: Call line
5 is homozygous for the variant CR2; cell lines 1, 2 and 7 are
heterozygous; and the rest of the cell lines are homozygous
for the common CR2. This is the first molecular weight Vi\ri1\nt
of CR2 found on the B cell surface. The variant is tcntiltivcly
designated CR2 L type, the letter L standing for lower
molecular ""eight. The common CR2 with higher molecular weight
is accordingly referred to as CR2 II type.
A family study: The above interpretation was further
supported by a family study (Fig. 6.11). In this family, the
father (lane 5) is a heterozygous carrier of the variant CR2
(H/L) and the mother (lane ~) homoz.ygous for the common CR2
(H/H). T'Jo siblings were also tested, showing that the son
(lane 3) is homozygous for the common CR2 (II/II), but the
daughter is heterozygous (H/L). An extra band was encountered
in the daughter 1 s sample (indicated by an arrow in fig. 6.11).
Recause the daughter's peripheral B cells were very difficult
to transform by Epstein-Barr virus under the standard
conditions, the typing test was done by using her peripheral
mononuclear cells (PMN).
In Fig. 6.11, are included another three cell lines (lanes
6-8) along with Jurkat (CR2-negative) (lane 9). Additionally,
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Fiqure 6.11. Inheritance of CR2 variant L allele in a family
(lane 1: Daughter; lane J: Son1 lane 4: Mother; lane 5:
Father). Lane 2 is a re-precipitate of lane 1 by polyclonal
anti-CRl. Lane 6-8: normal cell lines, and lane 9 is Jurkat.
d) 2
m.w.
Xl03
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lane 2 shown here is considered a control since the same
lysate was used for CR2 immunoprecipitation first (lane 1),
then the resulting supernatant was re-used for CRI
precipitation (lane 2). There are two bands seen in lane 2:
the top band of CRI of over 200 kDa, precipitated with a
polyclonal anti-hullIan CRI antibOdy (SEROTEC, Prince
Laboratories Inc. Toronto, Ont., Canada), and the CR2 L band.
The CR2 L band might be the remaining CR2 precipitates due to
incomplete clearing. The possibility that polyc1onal anti-CRI
cross-reacts with CR2 10w has not been excluded.
unfortunately, the family samples of the CR2 (L/L)
homozygote described above were not available, otherwise, more
infortniltion about the L variant would have been available.
'I'here was no CR2 polymorphism due to molecular charge
difference. As shown in Fig. 6.12, all the samples inclUding
an II/L heterozygous cell yielded an identical, single band on
the isoelectric focusing gel.
Allele frequencies: Although the sample group tested is
small (n=63), this new variant CR2 L with a molecular weight
of about 75 kDa .....as carried by six heterozygous unrelated
indiv iduals, and one homozygous individual. The allele
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Figure 6.12. :-<:;:oelectric focusing pattern of CR2 precipi t<.ltl:!5
from different cell lines, including the CR2 Ill! line (l<.lne 5)
and Raj i (lanes 1 and 13).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 +
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frequencies for both Hand L types were calculated (Table
6.4). The L frequency was over 0.01. It may be concluded that
CR2 size polymorphism exists in the population studied.
6.4. Characterization of epitopes on the CR2 novel variant
F1.ov cytometry: Since human CR2 acts as a receptor for at
least two ligands, c3d, Eve, and probably interferon-a, the
newly defined CR2 variant needed to be tested for any possible
changes in its specificity. such changes could, if found, be
due to loss of SCRs, o~· to comformational alteration. Its
molecular weight (about 75 kDa) is only half of the molecular
weight of the common CR2. Although the binding site for INF-a
on CR2 is unclear, the region for C3d and EBV binding has been
precisely localized at the first sen. There are three mAbs
with well-defined epitopes: OK8-7 recognizes the SCRs 1-2,
inhibiting both EBV and C3d binding; 118-5 recognizes the seRs
3-4; 82 recognizes the SCRs 9-14 (Fig. 2.2).
using thasQ thl'ee mAbs, several B cell 1 ines with known
phenotypes were first tested for expression of CR2 on the cell
surface (Fig. 6.13). ,Jurkat is the negative and Raj1 the
positive control. The FS 8212 is the homozygote of CR2 l"".
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'1',Jblc 6. <1. Distribution of phenotypes ot hUlllao eN'-
Phenotypes Observed No. Percentage Expected No. l
Cll:! II/II 56 86.9 55. J
CI{2 II/f.. 0.09 7.4
CH2 L/I, 0.02 0.3
'I'ot.~l 63 100.0 63.0
c..:u:!~ /I ~ 0.~J1 d.L
-
1
r:U:~ ~ I.
-
0.063 0.10 < P < 0.25
0.009
0.265
1.633
1.907
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Figure 6.13. Flow cytomelric profiles of celilinc!.; slaincd
with three different mAb 10 human CR2.
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The three mAbs gave v irtually identical flow cytometric
profiles for each individual cell line but the profiles
differed between the cell lines. Also, the CR2 L/L homozygous
cell line, FS 8212, was positive for all the antibodies used.
In order to visualize directly the binding of biotin-EBV to
CR2 on the cell surface, human B cell lines were reacted vith
biotin-EBV and then stained with FITc-avidin. After washing,
relative amounts of EBV bound on cells were analyzed by flow
cytomctry. Flow cytometry dopiction of a Small group of cell
lines randomly selected is shown in Fig. 6.14. Clearly,
binding of EBV to these cell lines was extremely variable,
positive cells accounting for from 25 (FS 6230) to 99' (FS
56J7). The data were consistent with the profile of CR2
expression defined by using monoclonal antibodies (Fig. 6.13).
ThUS, an analysis of the binding property of CFt2 on each cell
line could only be made by its own pair comparison under
inhibitory or non-inhibitory conditions.
The cell line rs 8212, which was homozygous for CR2 LlL,
was chosen for the investigation of the CR2 L variant binding
specificity. The experiment was carried out in several ways.
Dasidas a direct test, as described abov"",, three kinds of
inhibitory tests were included. In the first pair of tests,
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Figure 6.14. Flow cytometric profiles of cell lines rei:lcled
wilh biotin·EBV and stained wilh File-avidin. Non·reacted
Raji is included as a negative control.
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cells were incubated vith the inhibitory (refers to inhibiting
binding of EBV and C3d) ar'.;i-CR2 1IIonoclonal antibody OKB-7
either before or after addition of biotin-EBV, In the second
pair of tests, the conditions were the same, except for use of
IIB-5, a non-inhibitory anti-CR2 monoclonal antibody instead ot
OX8-7. In the third pair of tests, cells vere either incubated
with biotin-EBV, or with biotin-EBV pretreated with 1Ionoclonal
antibody 72Al (whlch is specific for gp350/220, the EBV ligand
for CR2). The results of these tests are shown in Fig. 6.15.
Undor non-inhibiting conditions (lina 1). approximately 40' of
the cells of the FS 8212 line bound biotin-EBV. When cells
were pre-incubated with anti-CR2 monoclonal antibody of either
118-5 (1 inc 3) or OKB-7 (line 4) prior to the addition of
biotin-EBV to cells, the percentages of positive ce.ls were
reduced by about a quarter, down to about 30\. Whan anti-CR2
antibody OKB-7 (lino:: 2) WilS added after the biotin-EBV pre-
incubation of cells, the percentage of positive cells was
unchanged. Furthermore, the EBv-neutralizing !'tAb 72Al, which
specifically binds to the pg350/220 of EBV, did not show
complete inh ibi tion of biotin-EBV binding to CR2. The
inhibition was incomplete irrespective of whether the antibody
was added after incubat:.ion of cells with biotin-EBV (line 5),
or the biotin-EBV was first neutralized with the antibody and
then added to the cells (line 6).
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Figure 6.15. Flow cytometric profiles 01 cell line:; reacted willI Iliulin·r::nv
before or aflerlreatmenl with mAb 10 human CR2. Line 1 ::1"10 'I~; hindinn
of biolin-EBV to the three cell lines, Jurkal, FS U?12 (UL rhf!Olllypf:) ,md
Rajl (H/H phenotype). In fine 2, cell lines FS B21:::: anrl R;lji Wfm~ fir::1
reacted with biotin-EBV followed by reaclion with rnAh OKB-! (::ce Ir~y.1
for further details).
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In contrast, with the reference cell line Raji, about 26\
of the cells were positive under non-inhibiting conditions.
When the antibody OKB-7 was added atter the biotin-EBV pre-
incubation of cells, the percentage of positive cells was
unchanged (the actual reading was 31\). However, when the
cells were incubated first with OKB-7 and then with biotin-
EBV, the percentage of positive cells dropped down to 14\. The
lowest binding of EBV was found when biotin-EBV was pre-
neutralized with mAb 72Al.
In summary. the cell, FS 8212 carrying the variant CR2
molecule, has not lost its EBV binding capacity. There are at
least two explanations. The partial inhibition of EBV binding
by OKB-7 rnAb might indicate conformational changes of the
variant CR2 so that it still can bind to EBV and/or CJd
ligands. unfortunately, an attempt to do the CJd binding assay
failed due to technical problems. On the other hand, the data
might suggest that another Ilolecule rather than CR2 serves as
a receptor for EBV on these cells.
G.5. The immunoregulatory functions of CR2
Animal models were establ ished to investigate the role at
CR2 in the regulation of immune responses. By following
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different protocols, the primary and secondary antibody
respons<ls .i.n.....Yix2 could be evaluated. These experiments are
presented in the follol.-1og two sections.
6.5.1. The influence of CR2 on the primary antibody responses
The protocol for the following experiments is illustrated
in Fig. 6.16 and described in Materials and Methods.
suppression ot primary response 19M but not 1qO by IIIAb to
CR2 (706): As shown in Fig. 6.17, the first experiment
included the 7G6-treated groups and the PBS-r.reated control
groups, with four mice in each group. Mice treated with 200 ug
of 7G6 mAb in 0.2 ml PBS or 0.2 ml PBS alone were immunized 24
h later with 100 or 200 ug of Ag. IgM and IgG responses were
tested from day 3 (72 h) to day 18. In mice pretreated with
PBS only, IgM and 19G peaked on day 5 and day 8, respectively.
Compared to these, the 7G6-treateu mice had substantially
depressed 19M responses but nearly normal IgG responses,
irrespective of the dose of Ag used. Based on stul1cnt' s t
test, highly significant differences between the 7G6-trcated
group and the control group were found in the IgM response
!rom day 3 to day II, especially when 100 ug of 1'.g
(on day 5 and 8)
1 i
~ r
Ag
(after 24 h)
Cobra Venom Factor (CVF)
Anti-CR2
Anti·CR1
AnIi-B220
ELISA ELISA
(on day 45)
i
i
Ag
boost with 6.25 ug
(on day 40)
Figure 6.16. The protocol for evaluation of CR influence on the
primary antibodv response.
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were used. In contrast, no significant differences were found
between the two groups in the IgG response.
suppression of primary antibody reapona8B by CVJ" VB mAlt to
CR2: In the next experiment, mAbs 7GG, RAJ-GB2 as well as CVF
were tested in parallel. The mAb RA3-GB2 reacts with the B
cell specific molecule 8220, and served as a control (Fig.
G.1B). Suppression was again seen here, 7G6 inhibited IgM (day
5) but not IgG. In contrast, the control mAb (RA3-GB2) did not
depress e;ither the IgM or the IgG responses. The suppression
of IgM production by 7G6 was highly signiticant, according to
avaluation by one-way ANOVA. If the present experiment is
consilliered a repeated test for confirmation of the conclusion
from the previous experiment, student I sane-tailed t test (7GG
treated group versus PBS treated group) still shows a
significant difference on day 5.
These preliminary results as \oIell as data published by other
investigators have demonstrated that the primary antibody
responses to a variety of T-dependent antigens can be
depressed by both CVF and mAb to CR2. A direct comparison of
the effects of these two reagents is made here to address the
question of whether they do in fact have similar effects, a
question \oIhich has not been addressed in previous
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pUblications. surprisingly, CVF suppressed IgG only ....hereas
m.\b to CR2 (7G6) suppressed IgM (Fig. 6.18). suppression of
IgM and IgG was followed throughout the entire experiment
(from day 1 to 11) without any changes, ~ the IgM response
in 7G6 treated mice remained suppressed from day I, the IgG
response from day 8 in CVF treated mice. The inactive CVF did
not suppress either 19M or IgG (Fig. 6.19), when the three
groups (Inactivated CVF-treated mice, CVF-treated mice and
PBS-treated mice) were compared. Effects of different
monoclonal antibodies against CRl!CR2 were also compared. Both
7G6 and 7E9 recognh;e CRI as well tiS CR2 while SC12 is
monospecific for CRl. As shown in Fig. 6.20, IgM production
can be depressed by either 7G6 or 7E9, but not 8C12. In
addition, 7E9 also inhibits the IgG response while 7G6 in this
experiment actually enhanced the IgG response. The precise
binding sites of 7G6 and 7E9 on CRl/CR2 are unknown.
Effect: of pretreatment with 706 on secondary respons83:
Forty days after the primary response, the mice were boosted
with I\g to see if pretreatment with CVF or rnAb to CRl/CR2 had
a long term effect on secondary antibody responses. Under
norm;ll circumstances optimal secondary antibody responses can
be achieved with a dose of 6.25 u9 Ag (as will be shown later,
Fig. 6. 26). In the present experiment &;::ch primed mouse was
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given 6.25 ug free Ag in PBS and bled five days later for
ELISA tests. The data in Fig. 6.21 suggest that the 7G6- and
7E9-treated mice had impaired secondary responses. As shown
earlier (Fig. 6.19), 7E9 mAb suppressed both pr.;mary IgM and
primary IgG production. From these experiments it may be
concluded that pretreatment of mice with anti-CR2 mAb may lead
to an impaired generation of immunological memory. On the
other hand, CVF, regardletHi of whether it is given in the
active or inactive form, has little influence on the secondary
antibody response. Anti-CRl (mAb 8C12) also has minimal effect
on the secondary response.
Influence of pretreatment wi tb CVP or IIlAb to CR on I9G
subclass responses: To further assess precise changes, IgG
subtypes in the secondary antibody responses have beo.!n
determined. Pretreatment with mAb to CR2 suppressed IgGz• and
IgG2b but had no or little effect on IgG 1 and IgG3 (Fig. 6.22).
Compared to the control group (PBS-treated), mice pretreated
with RA3-6B2 or CVF (active or inactive) showcd no notable
changes in any of the IgG subclasses.
Effect of anti-CR2 treatment on establishe4 I1D11luno1091cal
memory: As described above, mice treated with mAb to CR
(particUlarly, 7G6 mAb to CR2) 24 h prior to immunization
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showed both diminished IgM primary response and illpaired
imlllunological .emory. Once mice had developed nOrllal priaari"
and secondary responses, however, their ilrlJllunological ~e.ory
....as not. affected by t.reatllent with mAb to CR2. Four groups of
aice were boosted ",ith Ag on day 180. They had been injected
with IllAb or PBS on the previous day (day 179). As shown in
Fig. 6.23, all mice, irrespective of treatment, produced the
same amount of specific antibody.
Role of CR2 in the secondary antibody response
The protocol for the following experiments is illustrated
in Fig. 6.24 and described in Materials and Hethods. Here, the
antigen is targeted by IIAb to the B cell or the follicular
dendritic cell.
Ititletics of primary antibody response: A group of four
mice was iJuunlzed with 200 ug of Ag per mouse and the lIice
",ere bled at different tilles afterwards, from day 3 to day 18.
IgM and IgG responses were monitored by ELISA. As before (Fig.
6.17), IgM peaked on day 5 and IgG peaked on day 8, then both
gradually declined. By day 18 the level of specific IgG
appeared close to the normal range of IgG, whic:h is i.,dicated
by upper and lower dashed lines (Fig. 6.25).
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Figure 6.25. 'fillle-course analysis of the ru"illl.II"Y ~'1,,·,:jl i.: 1'1';
response to antigen (200 ug of CjO<lt hIt; F{.,Il'1 ,). All
used for ET~TSI\ were diluted ]/1000. 'I'llIJ 1"1.,:011]1:: ;,-r. o 1""::"111,-<1
as mean ± SO of four mjce per qrollp. lJpl":" dud 1'M'"' ,1.,::1,..<1
lines denote the 95\ confidence intcrvdl 01 nil- Ill,i/nu"u,i7.'·,j
controls.
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Seoondary antibody responses to different dOSflS of ),9: To
determine the amount of II.g needed for induction of a secondary
antibody response, mice were immunhed initially with 200 ug
of 1>.9 per mouse, then boosted with decreasing doses of Ag,
from 100 ug to 0.0625 u9. Four days later, the mice were bled
and the secondary antibody response examined (Fig. 6.26). It
was found that the secondary antibody response could be
induced by a minimum of 6.25 ug II.g. Higher doses did not
SUbstantially increase the response, and secondary responses
were poor when less than 6.25 ug of Ag was given. 'rhus, in
this case 6.25 ug of 11.9 was the minimal dose required for the
secondary response.
Efficiency ot Ag complexed with anti-CR2 !DAb for induotion
of socondary response: In these experiments the antigen was
targeted to the B cell or follicular dendritic cell with mAb
to evaluate CR2 function in the secondary immune response. Two
separate experiments were conducted for boosting the primed
mice with different doses of complexes. One was undertaken on
day 14. similar to that describeJ above for free antigen. The
other was done on day 40 when measurable amounts of specific
antibodies from the primary response had disappeared. The
IS3
<.oe~~ Cud
Figure 6.26. The effect of antigen do~c on w~o.;olldilrv 1·'·:;1'fIIl: .. ·.
The antigen was administered on dav 1 <l <lmJ 1:11<: ""ll,il,ndy
dotected by El,ISA. on day 18. (I) bol.ot'C licK>!;!: .. lid ([I) 1,1 t.,·r
boost. Each bar represents mean:!: Sll of IOllr m;CI! I,nl" IlffllJp.
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results are presented by optical density values, as mean ± SO
for each group for the first experiment (Fig. 6.27) and as
individual data for each animal for the second experiment
(Fig. 6.28). The amount of specific antibody in ng/ml was also
calculated for the second experiJlent (Table 6.5). These
experiments both showed that the secondary antibody responses
wer-e enhanced when the antigen was complexed with anti-CR2 mAb
(7GG) , particularly when tr-ace amounts of antigen (0.0625 \lg)
were used. There was no secondary response to the antigen at
this low dose when given as uncomplexed antigen (Fig. 6.26).
When anti-E220 mAb (RA3-6B2) was used, the secondary responses
wore only modestly improved. To demonstr-ate that the secondary
<lntibody response was specific for Ag (goat IgG F(ab'12
fragment). the antibody responses to rat IgG (mAbs 7G6 and
nAJ-GB2) were simultaneously monitored by ELISA. These
responses were primary responses (lgM) and specific mouse IgG
antibody to rat was very low (data not shown) •
Specific IgG subclasses were also tested for the second
c:xperiment. Apparently, the elevated antibody response was
conferred by more production of IgG21 and IgGlb • as indicated
in Fig. 6.29. IgG1 and IgGJ levels seemed not to be affected.
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Figure 6.27. !'iecondary rczpon:o:c to eli llt'n'lIt 011,::":; ,,'
complexed antigen on day 14 (F.xp. 1). All :;(-1-" w,·n· IIi 1111,~1
1/1000. (_) Ag alone; (0) 1\9 i- "JG(, (~,"ti-r;lt?); t~l) "''I I \(/\1-
682 (anti-n220). The dilta prczcnt llCilll ! :'ll 01 I.llp',· ",i.:.- I"'r-
group.
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l"irJlIl'C c,. ?fJ. Secondary response to different closes of
complexed illlt.igcn on day 40 (~;Kp. 2). All sera were diluted
1/1000. (1) O.062~ IIg /l,g; (2) O.62S lHJ Ag; (3) 6.25 ug Ag. The
d.lt .. iln~ reported as spots reprcsenting individual mice. The
,llllmi,ls were bled ~ days uftcr being boosted.
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Table 6.5. Quantification of specific rgC by ELISI\.
1.0<)10 IlJG
.g (ug)
'9 form cOl1ccntra tj on (nlJ/m1) l' **
O. 0625 Ag alone 1. 39 ± o.oe :.!·1. "/0
Ag + 7G6 2.35 ± o. JJ 22';.26 <.01
Ag + RA3-6132 1.46 ± 0.12 211.UO N~
0.625 Ag alone 1.04 ± O. JO GIl.UJ
Ag + 7G6 3.35 ... 0.41 22S"/'U7 <.01
Ag ... RA3-GD? 1.02 ± 0.49 66.34 t1~;
6.25 Ag alonet 3.18 ± (1.79 1 ~2!.i.1l
Ag ... 7G6 3.6'\ ± Cl.Jl '1 :w;~ . :~"I w:
Ag ... RA3-6D? 3.J5 0.20 22·1!.i.tl) 1I ~;
The sandwich ELISA was performed, as described in r'l~ltl<I'i ;11:;
and Methods.
* Geometric mean (Clntilog of the 109\0 IrJC com.:cntr'ltinn).
** determined by one-wCly ANOVf\, ilnd then comp;ll·{.H..I with t.ll{'
'-jroup of 1\g alone, if necessary.
t three mice in this group.
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FilJure (,.29. Jl)G subclasses in tho scconllllry response to
dirrCl"Cnt doses of complcxcd antigon on day 40 (Exp. 2). All
:~~nl were dj luted ]/]000. (.) Ag .110no; (0) Ag + 7G6 (anti-
Cll;!!: (1)1) f\CJ --- RAJ-G07. (anti-B220j. The datil present mean:!: SO
nl c,lcl1 'Jrollp. (1) (J.0625 lll) 1\CJ; (2) O.G?5 11<) II(]; (3) 6.25 ug
1\•.1. (.1) lqG S\lbcl<lSS ,levels on dily >10 (before boost).
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CHAPTER 7
DISCUSSION
7.1. Factor H typing
'1'he study of genetic polymorphisrns of proteins is usually
carried out through analysis of size, charge and antigenic
determinants. The search for charge differences is classical1 y
done by electrophoresis or isaelectric focusing of
serum/plasma samples followed by the identification of the
particular protein. These techniques have baen fruitFully
applied to the study of polymorphisms of complement proteins.
and almost all the proteins of the complement system have been
found to be polymorphic. Functional differences have been
suggested or described for some components. such as C4A versus
C4B (Lawet at.. 1984).
Factor H is a single-chain glycoprotein with a molecular
weight of 150,000 daltons in plasma. It belongs to the family
of complement activation regulators. and functions both to
accelerate the decay or alternative-pathway CJ convcrtase
(CJbBb) and as <" cofactor for factor I in the breakdown of CJb
to iCJb. Polymorphism of factor H was first described in 198'\.
IfJl)
So far, five genetic variants (FHI-FHS) which differ in
isoel€.ctric point have been identified (Rodriguez de Cordoba
and Rubinstein, 1984, 1987).
The present study was carried out w-ith the purpose ot
simpl i.tying the typing procedure and establishing factor H
allele frcquencies for the Newfoundland popUlation. The
protocol described by Rodriguez de Cordoba had some
experimental disadvantages. For example, tor
immunoprccipitation, a considerable amount of anti-humJlon
factor H antiserum (at least 100 ul) was needed for each
sample. Sometimes such a requirement for a routine test 1s
impractical Clnd unecononical. These limitations are obstacles
to human popUlation studies.
The approach presented here employed the sensitive
irnIDunoblotting technique. Alllounts of less than 5 ul human
serum were enough for the test, and the experimental costs in
time and antibody w-ere much low-er~ This method meets the
genera.1.. requircfllents for a popUlation survey, and may easily
be adopted by other laboratories.
The reliability of the revised method was verified by Dr.
nodrigucz de Cordoba, who, by means of his original method,
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re-typed a small group of samples with phenotypes defined in
our laboratory, confirming th.:lt the data obtained by these two
methods were consistent with each other. By typing a group of
129 local unrelated individuals, WI'! found that the frequencies
for two common alleles, FH*l and FH*2, in our population (Zhou
and Larsen, 1990) and the data previously reported for Now
York City, were comparable (Rodriguez de Cordoba and
RUbinstein, 1964). There were no rare variants of factor II
identified in this study.
A possible association between factor II vari.ants and
susceptibility to rheumatoid arthritis was also tested.
Although some HLA molecules are strongly assac lilted with
susceptibility to this autoimmune disease, the actual
pathogenesis is still largely unknown. It has been suggested
that early complement components may participate in and/or
accelerate the course of autoimmune diseases since these
components playa role in the clearance of immune complexes,
the generation of immUnOl"egulatory factors, iml'" inc complex
solubilisation, and viral neutralization. Therefore, factor II,
as a regUlator of C3 convertase, might be associated with one
or more autoimmt:ne diseases. This might suggest that there
were functional difference between the factor fl variants. The
data, obtained from 111 patients with rheumatoid arthritis in
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this study. did not reveal an association between the disease
and any factor H alleles.
In a lIIore recent report, an alternat've .ethod for ~actor
H typing has been described by Nakamura et al (1990), who used
a hOI:izontal, ultra thin-layer polyacrylamide slab gel for
isoclectric focusing of factor H in serum. They found that
there were three common phenotypes of factor H and five rare
patterns in Japanese. The existence of a null allele was also
suggested. Family studies confirmed that this factor H
polymorphism is controlled by two common alleles. However,
there was no correspondence between the common alleles defined
by this technique and those so far reported by Dr. Rodriguez
de Cordoba and in our stUdy. This raises the question of
whether there are two polymorphic syste.s of factor H.
AS mentioned earlier (in CHAPTER 2), human factor H does
appear in three forms in plasma. The 150,000 dalton molecule
i~ the common one; the 47,000 and 43,000 dalton molecules are
truncated forms, produced as a consequence of alternative mRNA
spl icing of the common transcript. It is not known ....hethar
these two truncatad forms are also polymorphic. Obviously,
more studies of different populations are required and the
relation between the two polymorphic systems must be
ICl3
clarified. Finally, the nomenclature for factor H variants
should be unified in the next Complement Genetics Workshop.
7.2. Factor I typing
Factor I is a regUlatory enzyme which cleaves and
inactivates C3b and C4b in the presence of co factors. Genetic
polymorphism of factor I was first demonstrated in a Japanese
popUlation (Nakamura and Abe, 1985). Two common alleles, IF''''A
and IFwB, were identified.
The original purpose of this study was to explore the
factor I phenotypes in a Caucasian population. A large group
of samples from the local caucasian community was screened.
Surprisingly, an identical pattern was observed in all the
samples tested. It was initially suspected that the method
employed was inappropriate. However, when a panel of reference
samples from Drs. Nakamura and ¥uas't were included on the gel
side by side with test samples, the reference samples c'id show
the expected patterns. Sera from a Slnall group of local
Chinese donors were then tested.
In total, 305 individual samples (28S caucasian and 17
Chinese) were typed for factor I. No IF A phenotype
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observed in the Caucasian samples. However, a neY variant was
identified, and confirJlled Yhen the family was typed (Zhou and
Larsen, 1989). In co:.trast, of the 17 Chinese individuals
tested 1 were IF AB hetero:zygous. Thus, it appears that the
IF"A allele, which occurs quite frequently in sOllie Asian
populations, se€lms to be present in Caucasian populations at
a very low frequency if at all. This phenomenon was also
notic€ld a few months €larlier by Yuasa et al (1988), ...·ho
studied factor I in a French population. A geoqraphical
distribution of the IF"A allt:!le is shown in Fig. 7.1 using
data from several reports. The combined data suggt:!st the
existence of a geographical cline for allt:!lt:! IF"A from Europt:!
to Japan. The Nepalese are characterized by an interrtlediate
value between the Prench and the Japanese, reflecting a point
of contact bt:!twec.n Mongoloids and Caucasoids. These findings
suggest that factor I nay be useful for anthropogenetic
studies, and further investigations in other ethnic groups
(such as Amerindians and Australian aborigines) would be of
interest.
In the VIth Complement Genetics workshop, factor I
reference typing was examined, and the nomenclature for factor
I allotypcs was officially dt:!signated according to thQ
di.rection of each variant's pI relative to two common types.
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So far, four variants have been found and named, including the
two co_on ones IF A and IF 8, and two rare variants IF Al
(Nakamura et al., 1990) and IF 81 (defined in this study).
7.3. CR2 typing
Human CR2 is a 145 kDa integral membrane glycoprotein. The
primary ligand for CR2 is CJd, a processed forn of C3 which
results from factor I-mediated proteolytic cleavage of C3b.
CR2 also serves as the Epstein-Barr virus receptor and
probably the receptor for interteron-a (Delcayre et al.,
1991). As a member of the family ot Regulators of Complellent
Activation, the CR2 molecule contains multiple copies of the
60 amino acid short consensus repeat (SCR). Recent experiments
have sholom that the gene encoding CR2 is within a region on
chromosome 1q12 which also contains the genes for CRl, HCP,
OAF, C4BP and factor H (Weis et al., 1987; Lublin et al.,
1987,1988; Hing et al., 1988). Polymorphic variants have been
described for all of these proteins with the exception of CR2
(liourcade et aI., 1990).
Even though CR2 and CRI evolved via the same mechanism at
expilnsion of short consensus repeats (SCRs), there have not
been any variant forms of the CR2 protein identified that are
167
analogous to the polymorphic gene products of CRl. However, a
number of studies strongly suggest the existence of
polymorphism in the CR2 protein at the structur31 level. The
first evidence came from the characterization of two forms of
CR2 eDNA isolated from a single tonsillar library (Weis et
al., 1987). Further studies on the sequence of the variant
cDNA clone led to the identification of several nucleotide
changes, indicating changes in the amino acid sequence of the
protein (Moore et a1., 1987; Toothaker et al., 1989). These
changes may reflect different CR2 alleles existing in the
human popUlation. Further evidence came directly (rom the
study of RFLPs of the CR2 gene, using Taq 1 or Hac TIl
restriction enzymes (Fujisaku et al., 1989).
The present study demonstrated, for the f i rat time,
polymorphism of human CR2 at the protein level. The CR2
molecule of 145,000 daltons which is the common product of the
CR2 gene, co-exists in the population with a variant CIU
molecule of about 75,000 daltons. This observation was based
on SDS-P.&.GE analysis of EBv-transformed B cells from different
individuals. The two forms of CR2 protein were tentatively
designated Hand L, rt.presenting CR2 variants with high (14S
kDa) and low (75 kDa) molecular weight, respectively. The
pattern of inheritance of the Hand L variants was consistent
IfJH
with autosomal codollinant expression of two alleles, based on
family data where the father and the daugh.ter are H/L
heterozygous but the mother and the son H/H homozygous. A
homozygous individual of L/L type as well as six heterozygous
individuals were also found within the group of 63 samplea
tested. The observed frequencies of three phenotypes did not
differ from those predicted by Hardy-weinberg equilibrium
based on gene frequencies of 0.937 and 0.063 for CR2 Hand CR2
L, respectively (Table 6.4). Although actual allele
frequencies of CR2 in a large population may Vllt"y slightly I
the fairly high frequency of the varl"1nt L allele suggests
that it is not a very rare allele and that this is a true
polYlllOrphi:::lI.
The R1echanisa by which the variant L protein was produced
is likely to be sillilar to that of the generation of CRl
variants. The variant L protein might contain only two LHR-
like segments, since its molecular weight was half of that of
the comlllon H variant composed of four UiR segments. Such
speculation, of course, must be confirmed by studies of
genomic DNA and/or cDNA sequences. This is beyond the
objective of the present project. In addition, functional
studies of the variant L protein may provide some new
ir.formation about the active domains of the CR2 molecule.
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As indicated in Fig. 6.10, the immunoprecipitate of CR2
from B cell lysates from some, but not all, individuals also
yielded an extra band with low, . molecular weight than CR2 L
on 50S-PAGE. The molecular weight of this extra band was
approximately 50 daltons. This extra band may originate from
one of several sources. Since B cell surface Ig molecules are
present in the cell lysates, the binding of CR2-anti-CR2
complexes to Protein-A could be contaminated with human BIg
molecules. This is unlikely, since all the cell Iysiltes had
been pre-cleared with Protein-A beads prior to cn2
precipitation and, even if the pre-clearing was not complete,
the extra band ""as not observed in all the samples. An
alternative explanation for the extra band derives from the
structure of the CR2 complex and its components. It is known
that human CR2 is usually associated with another cell
differentiation antigen, CDI9 (M<itsumoto et al .• 1991). as
well as with CRI (Tuveson et al., 1991), on B cells. III tile
studies of Matsumoto et a1. (1991), monoclonal antihvdics t.o
CR2 could co-precipitate the CR2-CD19 complex frof,' digitonin
lysates of Raji B lymphoblastoid cells. 'l'hree unidentified
components: p130, p40 and p20, werli! also co-precipitated.
Anti-CD19 precipitated four of these components, corresponding
to CR2, CD19, p130 and p20, but not p40. In the presence of
the nonionic detergent NP-40, anti-CR2 prp.cipitated only thre(!
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proteins, CR2, p130, and p40 whereas anti-CD19 precipitated
C019 and p40. but not t::R2, plJO and p20. Thus, p40 seems to be
tightly associated with both CR2 and CD19, depending on the
choice of detergent used. Therefore, it is likely that the
extra band presented here is p40, although other explanations
have not been excluded (such as proteolysis of CR2 or
alternative splicing of CR2 mRNA). variation of radioactive
density of the extra band among the different cell lines may
be the result of varying molar ratios of CR2 and p40. The
slight difference in molecular mass between this newly
identified extra band and p40 could be due to the conditions
of 50S-PAGE analysis. The gel concentration used in this
laboratory was 7.5% while a 5-15% gradient gel was employed in
the studies of Matsumoto et a1. (1991).
7.4. Characterization of epitopes on CR2 variants by flow
cytometry.
The relationship between structure and function in the
variant L molecule was approached by flow cytometry. The
primary structure of human CR2 has been deduced from sequence
analysi~ of the ·cDNA (weis et al., 1987; Moore et al .• 1987).
Its extracytop1asmic domain is composed entirely ot 16 (or 15)
short consensus repeats of 60 amino acids that are typical of
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the Regulators of Complement Activation. Using a panel of
synthetic peptides corresponding to the sequences of the CR2
ligands, recombinant CR2 mutants, and monoclonal antibodies to
CR2, the epitopes on human CR2 specific for ligand binding
have been precisely defined (Lowell et I'll., 1999: Carel et
I'll., 1990). The binding sites for both C3d and Epstein-Barr
v~rus are mapped within the same or two very close segments,
spanning the first two SCRs of the molecule.
Analys.\.s of the binding specificity of the CR2 variant
molecule might yield information on a possible alteration in
function caused by change in molecular size. By means of
biotin-labelled EBY particles, flow cytometry of the binding
bet....een EBY and CR2 was carried out using different cell
lines. In general, expression of CR2 on the cell surface was
found to vary tremendously from one cell line to another. 'I'his
is very similar to variation observed for CRl expression.
There were several monoclonal antibodies available for testing
the specific epitopes of the CR2 molecule (Lowell et I'll.,
1989; Carel et I'll., 1990). OKB-7 can block both C3d and EDV
binding site(s} on SCRs 1-2 of C.f.;2; neither HD-5, whict,
recognizes SCRs 3-4, nor B2, specific for SCRs 9-14, can do
so. The data presented here showed that the CPl variant L
molecule had retained its epitope for EBV binding, indicating
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that its function in terms of reaction with this liganJ was
unchanged in spite ot: the reduced. molecular mass.
Honoclonal antibodies to SCRs 1-2 (OKB-1), 3-4 (;18-5) and
9-14 (B2) all bind the variant CR2, suggesting that all these
SCRs spanning "WR-like" 1, 3 and at least part of 4 of the
CR2 molecule are present on the variant .olpcule. The
mechanism responaiblG for the reduction of 1I'l0h!cular mass is
unknown. Based on the positive reaction with mAbs OKB-7, HB-5
and 82, it would appear that SCRs 1-2, 3-4 and 9-14 are
present. This leaves SCRs 5-8 and 15-16 unaccounted for.
lIowcvcr. it would be surprising to find two non-consecutive
sequences of the gene either lost or not translated. It is
possible that there could be some alteration in post-
translational modification, such as glycosylation. on the
smaller CR2 L molecule, leadinq to the differential binding of
antibodies. The present study raises some doubts about the
defined locatio'l of the 82 binding site. Two previous reports
arrived at different conclusions. One mapped the 82 epitope to
SCRs 9-11 (Carel et al .• 1990) whereas another localized it to
SCRs 11-l4 (Lowell et a1., 1989). Therefore. DNA and mRNA
stUdies may be more useful to clarify the molecular basis for
the loss in size. Second, since the homozygous L/L cell line
was originally derived from peripheral 8 cells by EBV-
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t:.ransformation and because OK5-7 could only partially block
E5V binding to CR2, it is possible that there is a second
receptor indepelldent of CR2 to mediate t.he virus infect ion of
these cells. The finding of this homozygous L/L cell 1 ine may
provide a unique opportunity to study the mcc:.anj sm of lWV
tropism.
Summary
Genetic polymorph isms of factor Il, 1 and CR2 were
investi<:"ted by a combination of isoelectrofoc\lsinq ilnd
immunoblotting or by 50S-PAGE. The new method for factor" is
reliable and economical, and meets the general requirements
for a population survey. The a11el ie frequencies in the
Ne....foundland population were estimated from 129 unrelated
individuals to be 0.597 and 0.403 for FII*l and FII*2,
respectively. No assoc.:J.ation of factor If types with rheumatoid
arthritis was f.ound in 111 patients tested.
288 Caucasian individuals were typed for factor I, and 1:1
new variant, IF 51, was found. The phenotype IF All is lackJ;.~
in the population studied, indicating that the IP*A allele may
be present in caucasian populations at a very low frequf.lncy.
It may occur quite frequently in Asiatic populathns.
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For the first ti.'ne. CR2 protein polymorphis:n was
demonstrated. There art:l two variants, CR2 " (heavy) and CR2 L
(light). In 63 samples there were six hetcrozYlJotes and one
homozygote for CR2 L. Th~ inheritance of the CR2*/' allele \laB
confirmed in a family 5tudy. The CR2 L variant of 75 kDa may
represent the product of an allele varying in the :;umber of
short consensus repeats. Flow cytometry analysis of the
ligand/epitopes on CR2 L did not clarify the molecular basis
for the loss in size.
7.6. CR2 immunoregulatory functions
'l'hat the complement system is i1l1portant for humans .lnd
animals in mounting a normal antibody re5ponsc has been
demonstrated in a number of different ways. Treatment of mice
.... ith cobra venom factor (CVF) leads to complement depletion by
activating the alternative pathway and suppresses the antibody
response to both T-dcpendent and T-indcpendent ant igrms
(Pepys, 1976). Hereditary deficiencies in complement
components C2, C3 and C4, described in man, guinea pigs, ,lnd
dogs, generally lead to a depressed antH,,,jy respons(' and poor
induction of immunological memory (!3ottgcr et a I • , 1 'J65;
O'Neil et aI., 1988; Jackson ct al., 1919; Ochs ct al., 1903).
These data imply that the presence of CJ, a central element
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for both complement a(;tivation pathways, is critical for
induction of antibody respO:1ses, and that the impact of the
C)-activating factors C2 or C4 is probably secondary to the
actual effect of CJ.
Characterization of complement receptors has added to our
understanding of C3 function in immune responses. In humans,
ern is expressed on a variety of lymphoid cells. CR2
expresslon is mainly restricted to B cells although foIl ic.ular
dendritic cells, thymocytes and a small number of T cells have
also been shown to he CR2-positive (see p. 50). The role of
these receptors in immunoregulation has been demonstrated by
a number of experiments. For instance, monoclonal anti-CR
antibodies (particularly anti-CR2) induce human B cells to
proliferate and to secrete Ig~ (Wilson et a1., 1985;
Ncmarow et al., 1985), and aggregated CJb or CJd act as growth
and differentiation factors affecting pre-activated murine B
(,.,o11s (Erdei et a1., 1985; Malchers et al., 1985).
Studies of mouse complement receptors provided a means of
further determining the roles of CRI and CR2. Ther,,- is
appr,».:lmately 70%: identity .between the predicted amino acid
sequence of human CR2 and the Rlurine homologue (Fingeroth et
al., 1989; fingeroth, 1990). Both have the same molecular
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",eight, containing 15 SCRs. Murine CRI (MCRI) is a product of
alternatively spliced mRNA of the CR2 gene. Hence, .lmong thc
21. SCRs or the extraceillnar domain of MCRI there are only 6
unique CRl-1ike SCRs (Kurtz et a1., 1990; Molina et a1.,
1990). Similarities in structure bet"'een human CP.2 and
MCR2/MCRI make Tdice an appropriate cxperimental model in "'hieh
to study the function of complement receptors in...Y.iY2. nare,
a series of studies were carried out to explore the role of
complement ~eceptors in the regUlation of antibody responses
and in the induction of immunological memory.
7.6.1. RegUlation of the primary antibody response
The development of monoclonal anti-lymphocyte anlibodies
has greatly enhanced our ability to identify functionally
distinct cells of the immune system and to manipulate thesc
cells through their surface antigens. As a result, monoclonal
antibodies have become valuable tools in stud ies or the
cellular mechanisms underl} Ing immune responses. 'rhe great
advantage of monoclonal antibodies over antiscril is their
specificity for a single epitope of the antigen.
Previous studies have !':hown that mAbs to complement
receptors were able to depress the primary responses to a
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vi1riety at T-dependent antigens such as horse erythrocytes
(HRBC), sheep erythrocytes (SRBC), keyhole limpet hemocyanin
IKLH) and bactedal antigen (Sal.-onella), and to a lesser
extent, to T-independent antigens such as Ficoll and dextran
(Ileyman et al., 1990: Thyphronitis et al., 1991). The present
studies have confir1lled and extended the previous findings.
Furthe["Jllore, a direct comparison has been made between the
effects of CVF and mAb to CR2 in modulating humoral immun"!
rOGponsos.
Tho monoclonal antibodies to mouse CR1/CR2 used here are
thrce well-characterized rat 19G antibodies (Kinoshita et al.,
1988, 1990: Molina et aL. )991). 7G6 (lgGlb) is specific for
Ilur ine CR2 but cross-react-.s with CRI. 7E9 (lgGh ) also reacts
with murine CR2 as well as CRl. 8C12 (1gG2el is monospecific
[or lIlurine CRI and does not react with murine CR2. The anti-
0220 monoclonal antibody, RA3-6B2 (19Glbl was used as a control
aAb. The 8220 molecule (CD45) is a cell surface marker for
lIIature and itlllAature B cells, with a developmental profile
similar to that of CR2.
The results of this study can be summarized as follows: 1)
Injection of anti-CR2 prior to injection of antigen leads to
u poor primary IgM response, a normal primary 19G response,
and a poor secondary response when boosted 40 days later. 2)
Injection of CVF prior to injection of antigen leads to a
normal primary IgM response, a poor primary IgG response, and
a nonnal secondary response when boosted 40 days lat.er.
In order to explain these results, a scheme is presentcd
to outline a series of events, some hypothetical, which may
account for the experimental findings in this study. For the
sake of simplicity, interleukins have not been considered
here, assuming that neither CVF nor anti-CR2 af[e~t the T cell
responses. It is also assumed that cross} inking by Ag-l\b-
C3b/C3d complexes is a requirenment for a switch from TgM to
IgG. (Fig. 7.2).
As shown on the left 0" this figure, PBs-trcatcd mice
developed a nonnal primary response, producing both T9M and
IgG, and generating memory B calls. cVF-t rea ted mice,
indicated in the middle column, had a normal TgM response in
the beginning, and memory B cells were generated. Dut, the
switch to IgG induced by newly formed Ag-Ah-C3 complexes did
not occur due to C3 deficiency. In mice treated with anti-cR2,
sho....n on the right, it is hypothesil:ed that induction of
anergy led to decreased production of 19M and impaired
generation of memory B cells. But, the primary IgG rcsponGe
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Figure 7.2. A series of events, some hypothetical (underlined), after
pretreatmenls wilh PBS, CVF and anti·CA2 mAb, followed by antigen.
IHO
was normal, and Ag-Ab-Cl could induce the isotype switch. The
hypothetical events indicated in the figure are discussed
below.
The mechanism(s) by which mAb to CR2 suppress primary
responses appear to be quite different to those of CVF. One
difference may be the time of action. The interaction between
CR and anti-CR mAb presumably takes place very quickly aftor
a single injection of the mAb. In contrast, CVF WilS injected
several times over 24 h. CVF is unlikely to react directly
with the B cell. Instead, it probably first activates Cl, and
the C3-derived fragments bind to CR2 on the B cell. A second
difference is that the mAb probably cross links CR2 receptors,
while the monomer C3d fragments derived from activation of Cl
by CVF bind to CR but are unlikely to crosslink them.
Therefore, it is likely that pretreatment with anti-CI~2
depresses IgM response because of B cell anergy induced by a
single signal from CR2 without signalling via sIgM.
Finally, at a late stage in the anti-CR2 pretreated mice
appropriate crosslinking of sIgH and CR2 via Ag-Ab-C3d may
induce switching from IgM to IgG production. such swi tching is
unlikely to occur in the CVF-treated mouse which lacks C3. The
reason is that, although pretreatment with CVF has little
,.,
influence on the IgM response, newly formed Ag-Ab may have
baen removed from circulation while the mouse is still
complement det icient. One could test this hypothesis by
injecting anti-CR2 a few days after Ag h<,d been given in
animals made CJ deficient by CVF. One would here expect normal
IgG production.
That signalling via complement receptors somehow affects
the switch from IgM to IgG2 subclass, is also suggested by the
results of two experiments (Fig. 6.22 and 6.29). A normal IgG,
:..-esponse iE:. seen, but very little IgG2• or IgG2b is produced
when animals, treated with anti-CR2 or anti-CRI prior to the
first exposure to antigen, are boosted with antigen 40 days
later (Fig. 6.22). However, a normal IgG, response but an
increased IgG2• and IgGzb response is seen in animals boosted
with a suboptimal dose of Ag complexed with anti-CR2 (Fig.
6.29). 'I'his apparent association between CR signalling and
IgG2 production is worthy of further stUdy. A previous study
by lIebell et a1. (1991) also showed that a primary immune
response in mice to SRBC could be suppressed by a soluble
recombinant CR2, and only IgG, subclass was unaffected. If the
hypothesis that CR2 may preferentially influence class
switching to IgG2.J1gGZb can be proven to be correct, it may
provide one way of producing mAb of chosen subclass. We intend
1H2
to test this with a panel of IgM: secreting hy~ridoma9. A.
crith..:al requirement of such experiments will be that the
hybridomas are expressing membrane CR2.
This study differs from that of Heyman et a).• (1990) and
Thyphronltis et a1. (1991), who found that both 19M and JgG
responses were depressed in 7G6-treated mice. The discrepancy
may be due to time of testing, or due to I\g and Ag dose used.
Tha antigens used were HRBe and KLH (Heyman et a 1., 1990) or
FITC-haptenated antigens (Thyphronitis et aL, 1991). The
ELISA for both IgM and IgG wa~ performed 5 or 7 days later in
both studies. In the present experiments, normal primary 19M
responses could easily be detected by ELISA as early as day),
with a peak on day 5. IgG rcspons"s predominated on day 7 or
8. Only IgM was profoundly depressed in anti-CR2 treated mice
during the entire period of the primary response, althouqh a
higher dose (200 ug) of II.g had a slight compensatory effect.
On the other hand, the IgG response was virtually unaffected
irrespective of the amount of I\g used for immunization (Pig.
6.17) •
The different specificities of these monoclonal antibodies
may be responsible for their disparate effects. 7E9, like 7G6,
suppressed IgM (Fig. 6.20), but unlike 7G6, it also depressed
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the IlJG response. This spcculath!'l that specific epitopes on
CR2 ...ffect the immune response differently gains indirect
support from in......Y)M.g stimulation studies of human B cells.
One mAb (01<8-7) induced 8 cell proliferation when used alone
While another mAb (H8-5) activated B cells only in the
presence of anti-mouse immunoglobulin antibody which
crosslinks the H13-5 mAb (Nemerow et a1., 1985). Anti-CRl rnAb
BC12 had no effect on either response. In addition, the
results !1'Jggest that either the CRI molecule or, at least, the
BCI:?' epitope within the first 6 MCRI-specific SeRs (Molina et
a1., 1992), has little or no impact on the primary immune
response. This finding is consistent with a previous report by
Heyman et al. (1990).
Another explanation for the differential effects of these
monoclonal antibodies may be related to isotypes of the
antibodies used. In general, rat IgGlo antibodies more
effichmtly than 19G1 deplete target cells in vivo as these
cells circulate through the spleen (Seaman and wofsy, 1988).
However, this is unlikely to be the case in this stUdy since
Kinoshota et al. (1990) have shown that~ pretreatment
with 7G6 did not markedly decrease the number of B cells,
their size, or the expression of 8 cell sIgM, la, or 8220
antigens.
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7.6.2. Influenc(l of CR2 on memory generation
Although both the anti-CR2 mAbs (7G6 and 7E9) and CVF
suppressed the prImary response, only pretreatment with anti-
CR2 mAb affected the secondary antibody response. This finding
is similar to that of a previous report by Wiersma et al.
(1991). In addition, impairment of the secondary response to
optimal doses of Aq was seen in 7G6-pretreated mice but not in
mice treated with CVF, RA3-6B2 or PBS. This agrees with an
earlier observation of Pepys (1974), who demonstrated that. CVF
treatment prior to a primary response had a stronger effect
than the same treatment prior to a secondary response. It
appears that a good primary IgM response was followed by the
generation of memory B cells, ensuring a good secondary
response. In contrast, a good primary IgG response in itself
mayor may not guarantee a good secondary response (.i.....£...... no
memory cells produced). One might speculate that B cells
secreting IgG in a primary response do not differentiate into
:memory B cells, and that sIgM bearing B eel Is seem to be a
major population involved in primary IgM production and mt>mory
generation.
On the other hand, the present experiments may suggest that
sIgM-CR2 co-expressing B cells prefe,rentially become anergic
lH5
when treated with anti-CR2 prior to Ag stimulation, and
therefore memory B cells will be lacking. However, as shown
above (Fig. 6.23) once immunological memory is established,
treatment with anti-CR2 does not induce suppression of a
secondary response. This has also been found in the study of
Thyphronitis et al. (1991).
7.6.3. Augmentation of secondary antibody response by Ag
complexes through CR2
One of the numerous differences between the primary
response and secondary response is the lower requirement for
antigen in the secondary response. A second difference between
the two responses may be that different populations of antigen
processing/presenting cells are :nvolved. Although macrophages
playa major role in antigen handling (this may be considered
the "classical antigen pathway"), B cells are not only capable
of presenting antigen to T cells but also do
effec",ively, at least in the secondary response.
The immune system consists of many highly organized
microenviroments, one of which is the germinal centre (Ge),
located within follicles of peripheral lymphoid organs such as
1ymph nodes and spleen (Tew et al., 1990; Schriever and
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Nadler, 1992; Kosco and Gre.y, 1992). Genlin" 1 centres develop
transiently in response to an antigenic challenge, and through
this development, antigen-specific lIlemory B cell clones are
ger-erated, and switching of the illllllunogiobulin isotype and
selection of clones with high affinity due to somatic
llIutations occur. Germinal centres contain a unique type or
accessary cell, the follicular dendritic cell (FOC). The
principal feature of all FDC is their ability to trap antJ<)cn
in the form of immune complexes on thei~ cell sut-faces. l3eilded
"bodies of immune complexes" '::In the Foe sut'face were
discovered by electron microscopy (Szakal et al., l'JRfl) and
are often referred to as "iccosomes". In this rorn;, antigen
could be taken up by GC B cells from FOC and presented to
helper T cells, and the reSUlting T-B cell interact ion leadG
to B cell proliferation. These steps have been proposed as tho
"alternative" antigen pathway (Tew et al., 1989), which
includes: immune complex foraation, immune complex trapping
and transportation to FDC by non-phagocytic cells with
dendritic morphology, iccosoJle fOllllation, endocytosis of
iccosomes by B cells, antigen processing and presentation or
antigen to T cells.
There is a growing body of literature to support the
concept that C3 is likely to be involved in the induction and
'X7
maintenance of melnory B cells. Initial evidence came from the
observation that mice depleted of C3 by CVF cannot localize
Ag-Ab complexes on FOe (Klaus and Humphrey, 19771 Klaus et
a1 .• 1980).
In this study, using a !nAb to CR2 instead of C3d fragments,
we have established an animal model in mice for evaluation of
the effect of CR2 on the secondary antibody response. To do
this, all mice w,~re first immunized with Ag to elicit a normal
primary response. Ag complexed with rnAb to CR2 was then used
to test whether direct targeting of Ag to B cells or FDC via
CR2 ligat ion can augment Ule secondary antibody response. We
assume here that in the form of an immune complex with anti-
CH2, antigens are likely to be handled in the same way as 1I.g-
Ab-CJJ complexes. The reBul ts demonstrate that the secondary
antibody response can be triggered with 6.25 ug of free Ag
[(goat F(ab')2 in this case)) in primed mice. ~:-.en less than
this amount of Ag is used, the secondary antibody responses
are barely detectable. However, when free Ag is ·.:::omplexed to
anti-CR2 mAb, a lOO-fold lower amount of antigen is capable of
inducing the secondary antibody response. The enhanced
antibody response was mainly due to the increased production
of IgG2~ and I~G2b subclasses.
18K
One possible explanation for these observations is that
administration of the preformed complexes may bind to Fc
receptors and/or activate host complement. C3 fragments
generated during activation may indirectly modulate the ilDmun~
response. If this occurred the effect should be the same for
both the anti-CR2 complex and anti-B220 complex. However .....hen
animals were challenged by Ag complexed \<lith anti-B220, the
amounts of Ag needed to induce the secondary response were
similar to those needed when 1\9 ....as injected alone. Nor fire
there reasons to believe that this occurs because of "loss" oC
1\g from anti-B220 complexes due to preferential binding or the
IgG Fc components of anti-B220 to FC, receptors on phagocytic
cells (neutrophils). Anti-CR2 (7G6) and anti-U220 (RA3-6B2)
are of the same isotype so a similar "loss" of I\g from antl-
CR2 complexes should have occurred.
A second possible explanation is that anti-t.t;.~ mflb in the
complexed Ag may mediate antigen binding directly to the D
cell. But, like anti-CR2. the control mAb aga inst 8220 should
also target Ag to the B cells. Different results may suggest
that anti-CR2 has a specific effect, either by signall ing via
CR2 en the B cells or by localiZing effectively the Ag
complexes on the FOC. Some pos~ible interactions to explain
the results of these experiments are summarized in Fig. 7.3.
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Figure 7. 3 Possible routes to B cel1 stimulation in the GC by Ag
complexed with anti-CR2 ('f ).
The mechanism by "'hieh anti-CR2 exerts immunoregulation of
the secondary antibody response might involve the CR2-
associated molecules on B cells and/or FOC since the 34 amino-
acid cytoplasmic portion of CR2 itself appears to be too short
to mediate transduction signals (Moore et a1., 1987; Weis et
a1., 1988). In humans, one of these molecules is CD19, II
member of the Immunoglobulin (lg) superfamily (Zhou et al.,
1991, 1992). Like CR2, CD19 is expressed on B cells throughout
all stages except the plasma cell stage. C019 has a long
cytoplasmic tail with the capacity for signal truosduction.
The involvement of C019 in 8 cell activation and proliferution
has been d"",umented in earlier studies (Carter et al., 1991).
Recent studies have demonstrated that the CD19 molecule forms
a multimolecular complex with CR2 and three other molecules
(Matsumoto et a1., 1991). Therefore, it has been proposed that
the C019 molecule serves as a signal tran:.:ducing element of
CR2. One set of in vitro experiments has shown that in the
prf"sence of saturating concentrations of mAb to CD19, the
threshold for B cell activation "'as lowered and the magnitude
of B cell proliferation was heightened when stimUlated by mAb
to slgM (Carter and Fearon, 1992). The present data are
consistent with these observations. In addition, the finding
of a physical association between sIgM and CR2 in humans
(Tuveson et a1., 1991) may provide another mechanism by which
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complement-coated antigens can stimulate B cells through
crossl inking of both surface molecules. Association between
CR2 and sIgM may occur in mice just as it does in humans.
Obviously, these two possible mechanisms (CR2-CDI9 and CR2-
sIgH) are not mutually exclusive.
In addition, the experimental results could be explained by
effective localization, via CR2, of Ag complexes on FOC
(Sellheyer et al., 1989; Schriever et al., 1989). FOC express
high levels of CRl and CR2, and the function of the FOC here
is probably to display the Ag complex so that antignn-specific
B cells can easily react with the antige!l. These B cells will
be stimulated in the presence of T helper cells. This would be
an efficient mechanism for generating large numbers of
antigen-specific plasma cells in a short period of time. Under
natural circumstances Ag-Ab-C3d immune complexes .iD..-..Y.iY2
probably function in this way. Hence, a subtle immune response
can be magnified, with the ultimate goal of eliminating
foreign antigen. Of course, our data de. not totally exclude
the possib1l::! involvement of CRl, but in mice CRl and CR2 are
products of the same gene.
Because of both the complexity of immune response, the
complexi ty of the complement system and the different, and
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often incomparable experimental conditions used in di fferent
laboratories, Some discrepancies bet....een our data and the data
of others are difficult to elucidate. For instance, sheep
erythrocytes (SRBCl, keyhole limpet hemocyanin (KLHI or
bacterial antigen (Salmonella) had been used as Ag (Heyman et
a1.. 1990; Thyphronitis et a1., 1991). Future experiments
should be carried out on transgenic mice made CR2 deficient
with the knock-out CR2 gene.
7.6.4. SUmmary
Immunoregulatory functions of CR2 were explored.in.....Y..iY2 in
an animal model. Pretreatment of mice with anti-cH2 rnl\b
significantly suppressed the primary antibody response (mainly
19M) to aT-dependent Ag, and impaired the generation of
immunological memory. It is hypothesized that these e(fects
might be due to the induction of B cell anergy. This
suppression was different from that initiated by cobra venom
factor (CVF) pretreatment. Treatment with anti-CR2 was unable
to eradicate an already established immunological memory. The
data also suggested that signalling via CR2 may preferentially
affect switching from 19M to 19Gr Finally, Ag comple)Ced with
anti-CR2, a physiological analogue of CJd-Ag-Ab. can evoke an
~ secondary antibody response at a lOO-fold lower 1'.9
193
dose than Aq alone, suqgestinq that anti-CR2 has a specific
effect, either by signalling via CR2 on the B cells or by
effectively localizing the 1\g complexes on the FOC.
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